0001615774-18-003642.txt : 20180511 0001615774-18-003642.hdr.sgml : 20180511 20180511170827 ACCESSION NUMBER: 0001615774-18-003642 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 52 CONFORMED PERIOD OF REPORT: 20180331 FILED AS OF DATE: 20180511 DATE AS OF CHANGE: 20180511 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Health-Right Discoveries, Inc. CENTRAL INDEX KEY: 0001537663 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 453588650 STATE OF INCORPORATION: FL FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 333-206839 FILM NUMBER: 18827856 BUSINESS ADDRESS: STREET 1: 18851 NE 29TH AVENUE, SUITE 700 CITY: AVENTURA STATE: FL ZIP: 33180 BUSINESS PHONE: 305-705-3247 MAIL ADDRESS: STREET 1: 18851 NE 29TH AVENUE, SUITE 700 CITY: AVENTURA STATE: FL ZIP: 33180 FORMER COMPANY: FORMER CONFORMED NAME: Four Plex Partners, Inc. DATE OF NAME CHANGE: 20111219 10-Q 1 s110106_10q.htm 10-Q

 

UNITED STATES 

SECURITIES AND EXCHANGE COMMISSION 

Washington, D.C. 20549

 

FORM 10-Q

 

QUARTERLY REPORT PURSUANT TO SECTIONS 13 OR 15 (d) OF THE SECURITIES AND EXCHANGE
ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2018

 

Commission file number: 333-206839

 

HEALTH-RIGHT DISCOVERIES, INC. 

(Exact name of registrant as specified in its charter)

 

Florida 45-3588650
(State or Other Jurisdiction of (I.R.S. Employer
Incorporation or Organization) Identification No.)

 

18851 NE 29th Avenue, Suite 700, Aventura, Florida 33180 

(Address of Principal Executive Offices)

 

(305) 705-3247 

(Registrant’s telephone number, including area code)

 

(Former name, former address and former fiscal year, if changed since last report)

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒  No ☐

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (ss.232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☐ No ☒

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

 

Large Accelerated Filer ☐ Accelerated Filer ☐
Non-accelerated Filer ☐ Smaller reporting company ☒
  Emerging growth company ☒

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No  ☒

 

The number of shares outstanding of the registrant’s common stock, $0.001 par value, as of April 14, 2018 was 22,869,191 shares.

 

 

 

 

TABLE OF CONTENTS

  

      Page
       
PART I – FINANCIAL INFORMATION    
       
Item 1. Financial Statements.    
       
  Consolidated Balance Sheets as of March 31, 2018 and December 31, 2017 (unaudited)   3
       
  Consolidated Statements of Operations for the three months ended March 31, 2018 and 2017 (unaudited)   4
       
  Consolidated Statements of Cash Flows for the three months ended March 31, 2018 and 2017 (unaudited)   5
       
  Notes to Consolidated Financial Statements (unaudited)   6
       
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.   16
       
Item 3. Quantitative Disclosures About Market Risk.   21
       
Item 4. Controls and Procedures.   21
       
PART II - OTHER INFORMATION    
       
Item 1. Legal Proceedings.   22
       
Item 1A. Risk Factors.   22
       
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.   22
       
Item 3. Defaults Upon Senior Securities.    
       
Item 4. Mine Safety Disclosures.   22
       
Item 5. Other information.   22
       
Item 6. Exhibits.   22
       
SIGNATURES   23

 

2 

 

 

PART I – FINANCIAL INFORMATION

 

Item 1. Financial Statements.

 

HEALTH-RIGHT DISCOVERIES, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(Unaudited)

 

   March 31, 2018   December 31, 2017 
         
ASSETS          
           
CURRENT ASSETS:          
Cash  $1,783,986   $1,458,942 
Accounts receivable, net   481,056    471,112 
Inventories   30,219    32,580 
Total current assets   2,295,261    1,962,634 
           
Property and equipment, net   22,212    10,592 
Intangible assets, net   4,080,434    4,196,717 
Goodwill   3,313,226    3,313,226 
           
TOTAL ASSETS  $9,711,133   $9,483,169 
           
LIABILITIES AND STOCKHOLDERS’ EQUITY          
           
CURRENT LIABILITIES:          
Accounts payable and accrued expenses  $1,343,984   $1,346,317 
Loans payable - related parties   —    33,512 
Salaries payable - related party   157,000    182,000 
Current portion - notes payable, net of discounts of $399,252 March 31, 2018 and December 31, 2017, respectively   265,196    265,196 
Total current liabilities   1,766,180    1,827,025 
           
LONG-TERM LIABILITIES:          
Notes payable, net of discounts of $658,026 and $757,829 March 31, 2018 and December 31, 2017, respectively   6,177,526    6,077,713 
Deferred tax liability   1,031,241    980,212 
Total long-term liabilities   7,208,767    7,057,925 
           
Total liabilities   8,974,947    8,884,950 
           
STOCKHOLDERS’ EQUITY          
Preferred Stock, .001 par value, 5,000,000 shares authorized No shares issued and outstanding March 31, 2018 and December 31, 2017, respectively   —    — 
Common Stock, .001 par value, 100,000,000 shares authorized 22,869,191 shares issued and outstanding March 31, 2018 and December 31, 2017, respectively   22,869    22,869 
Additional Paid in Capital   1,117,967    1,117,967 
Accumulated Deficit   (404,650)   (542,617)
Total stockholders’ equity   736,186    598,219 
           
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY  $9,711,133   $9,483,169 

 

See accompanying notes to unaudited Condensed Consolidated Financial Statements.

 

3 

 

 

HEALTH-RIGHT DISCOVERIES, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
FOR THE THREE MONTHS ENDED MARCH 31,
(Unaudited)

 

   2018   2017 
         
Revenue  $1,924,832   $— 
           
Cost of Revenue   376,096    — 
           
Gross Profit   1,548,736    — 
           
COST AND EXPENSES:          
General and administrative   1,103,462    18,767 
Interest expense - related parties   —    2,352 
Interest expenses - other   256,278    — 
Total cost and expenses   1,359,740    21,119 
           
Income (loss) before income tax provision   188,996    (21,119)
           
Income tax provision   51,029    — 
           
NET INCOME (LOSS)  $137,967   $(21,119)
           
Income (loss) per common share   0.01    (0.00)
           
Weighted average common shares outstanding - basic and diluted   22,869,191    17,533,332 

 

See accompanying notes to unaudited Condensed Consolidated Financial Statements.

 

4 

 

 

HEALTH-RIGHT DISCOVERIES, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
FOR THE THREE MONTHS ENDED MARCH 31,
(Unaudited)

 

   2018   2017 
         
OPERATING ACTIVITIES:          
Net income (loss)  $137,967   $(21,119)
Adjustments to reconcile net loss to net cash (used in) provided by operating activities:          
Depreciation expense   986    — 
Amortization   116,283    — 
Non-cash interest   99,813    — 
Deferred income tax benefit   51,029    — 
Changes in operating assets and liabilities:          
Accounts receivable   (9,944)   — 
Inventories   2,361    (16,672)
Accounts payable and accrued expenses   (2,332)   — 
Accrued salary to related party   (25,000)   13,000 
Accrued interest   —    2,352 
NET CASH PROVIDED BY (USED IN) OPERATING ACTIVITIES   371,163    (22,439)
           
INVESTING ACTIVITIES:          
Purchase of property and equipment   (12,607)   — 
NET CASH USED IN INVESTING ACTIVITIES   (12,607)   — 
           
FINANCING ACTIVITIES:          
Proceeds of loan from related parties   —    4,344 
Repayment of related party loan   (33,512)   — 
NET CASH (USED IN) PROVIDED BY FINANCING ACTIVITIES   (33,512)   4,344 
           
INCREASE (DECREASE) IN CASH   325,044    (18,095)
           
CASH - BEGINNING OF PERIOD   1,458,942    18,373 
           
CASH - END OF PERIOD  $1,783,986   $278 
           
Supplemental disclosures of cash flow information:          
Cash paid for interest  $159,374   $— 
           
Cash paid for income taxes  $—   $— 

 

See accompanying notes to unaudited Condensed Consolidated Financial Statements.

  

5 

 

 

HEALTH-RIGHT DISCOVERIES, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

 

NOTE 1 – Summary of Significant Accounting Policies

 

The significant accounting policies of Health-Right Discoveries, Inc. and its subsidiaries (collectively, the “Company” or “HRD”) were described in Note 1 to the audited consolidated financial statements included in the Company’s 2017 Annual Report on Form 10-K (“2017 Form 10-K”). There have been no significant changes in the Company’s significant accounting policies for the three months ended March 31, 2018.

 

Basis of Presentation

 

The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in conformity with accounting principles generally accepted in the United States (“GAAP”) for interim financial information and in accordance with the rules and regulations of the Securities and Exchange Commission.  Therefore, they do not include all information and footnotes normally included in annual consolidated financial statements and should be read in conjunction with the consolidated financial statement and notes thereto included in the 2017 Form 10-K for the year ended December 31, 2017. In the opinion of the Company’s management, the accompanying unaudited condensed consolidated financial statements contain all the adjustments necessary (consisting only of normal recurring accruals) to present the financial position of the Company as of March 31, 2018 and the results of operations and cash flows for the periods presented. The results of operations for the three months ended March 31, 2018 are not necessarily indicative of the operating results for the full fiscal year or any future period.

 

Use of Estimates

 

The preparation of the financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements and the reported amounts of revenue and expenses during the reporting periods. Actual results could differ from those estimates. Certain of the Company’s estimates could be affected by external conditions, including those unique to its industry, and general economic conditions. It is possible that these external factors could have an effect on the Company’s estimates that could cause actual results to differ from its estimates. The Company re-evaluates all of its accounting estimates at least quarterly based on these conditions and record adjustments when necessary.

 

Inventories

 

Inventories, which consist of the Company’s product held for resale, are stated at the lower of cost, determined using the first-in, first-out, or net realizable value. Net realizable value is the estimated selling price, in the ordinary course of business, less estimated costs to complete and dispose of the product.

 

If the Company identifies excess, obsolete or unsalable items, its inventories are written down to their realizable value in the period in which the impairment is first identified. Shipping and handling costs incurred for inventory purchases and product shipments are recorded in cost of sales in the Company’s statements of operations. In the first quarter of 2018 and 2017, the Company recorded a loss of $-0- due to management’s estimate of obsolete inventory. 

 

6 

 

 

Property and Equipment

 

Property and equipment are stated at cost. Expenditures for additions are capitalized, repairs and maintenance are expensed as incurred. Depreciation is provided using the straight-line method over the estimated useful lives of the assets, which are as follows: 

 

   March 31, 2018   December 31, 2017 
Machinery and equipment – 7 years  $31,801   $19,195 
Accumulated depreciation   (9,589)   (8,603)
Total property and equipment  $22,212   $10,592 

  

Financial Instruments and Fair Value Measurements

 

The fair value of a financial instrument represents the amount at which the instrument could be exchanged in a current transaction between willing parties, other than in a forced sale or liquidation. Fair value estimates are made at a specific point in time, based on relevant market information about the financial instrument. These estimates are subjective in nature and involve uncertainties and matters of judgment, and therefore cannot be determined with precision.

 

Accounting standards define fair value as the price that would be received from selling an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. Accounting standards establish a fair value hierarchy which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value and also establishes the following three levels of inputs that may be used to measure fair value:

 

Level 1 — quoted prices in active markets for identical assets or liabilities

 

Level 2 — Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities

 

Level 3 — Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities

 

The following methods and assumptions were used by the Company in estimating fair value disclosures for financial instruments:

 

● Cash and cash equivalents, restricted cash, operating lease related receivables, and accounts payable: The amounts reported in the accompanying Consolidated Balance Sheets approximate fair value due to their short-term nature

 

● Goodwill, other intangible assets, and long-lived assets held and used: The assets are measured at fair value when there is an indicator of impairment and recorded at fair value only when impairment is recognized or for a business combination. The fair values less costs to sell of long-lived assets or disposal groups held for sale are assessed each reporting period they remain classified as held for sale. Subsequent changes in the held for sale long-lived asset’s or disposal group’s fair value less cost to sell (increase or decrease) are reported as an adjustment to its carrying amount, except that the adjusted carrying amount cannot exceed the carrying amount of the long-lived asset or disposal group at the time it was initially classified as held for sale. [need to add the Level of inputs used]

 

7 

 

 

Stock-based compensation

 

The Company recognizes compensation expense for stock-based compensation in accordance with ASC Topic 718. For employee stock-based awards, the fair value of the award is calculated on the date of grant using the Black-Scholes method for stock options and the quoted price of our common stock for common shares; the expense is recognized over the service period for awards expected to vest. For non-employee stock-based awards, the fair value of the award on the date of grant is calculated in the same manner as employee awards. However, the awards are revalued at the end of each reporting period and the pro rata compensation expense is adjusted accordingly until such time the nonemployee award is fully vested, at which time the total compensation recognized to date equals the fair value of the stock-based award as calculated on the measurement date, which is the date at which the award recipient’s performance is complete. The estimation of stock-based awards that will ultimately vest requires judgment, and to the extent actual results or updated estimates differ from original estimates, such amounts are recorded as a cumulative adjustment in the period estimates are revised.

 

Earnings (Loss) Per Share

 

Basic earnings (loss) per share is computed by dividing net income (loss) by the weighted average number of common shares outstanding for the period. Diluted earnings (loss) per share is computed by dividing net income (loss) by the weighted average number of shares outstanding, noted above.

 

Recent Accounting Pronouncements

 

Revenue Recognition

 

As of January 1, 2018, the Company adopted ASU 2014-09 and all subsequent ASUs that modified ASC 606. As part of the implementation process the Company performed an analysis to identify accounting policies that needed to change and additional disclosures that are required. The Company considered factors such as customer contracts with unique revenue recognition considerations, the nature and type of goods and services offered, the degree to which contracts include multiple performance obligations or variable consideration, and the pattern in which revenue is currently recognized, among other things. All of the Company’s revenue streams were evaluated, and similar performance obligations resulted under the new standard. In addition, the Company considered recognition under the new standard and concluded the timing of the Company’s revenue recognition will remain the same. The Company has also evaluated the changes in controls and processes that are necessary to implement the new standard, and no material changes were required.

 

CCI’s revenue predominantly represents consulting services agreements, which included providing services to physicians for billing insurance companies. The amounts reported as revenue are net of amounts remitted.

 

8 

 

 

EZ’s revenue from the sale of products are recognized when the sale is consummated and title is transferred. The Company and customer enter into an agreement which outlines the place and date of sale, purchase price, payment terms, and the assignment of rights and warranties from the Company to the customer. Management has identified the promise in the sale contract to be the transfer of ownership of the asset. Management believes the asset holds standalone value to the customer as it is not dependent on any other services for functionality purposes and therefore is distinct within the context of the contract and as described in ASC 606-10. As such, management has identified the transfer of the asset as the performance obligation. The transaction price is set at a fixed dollar amount per fixed quantity (number of assets) and is explicitly stated in each contract. Sales revenue is based on a set price for a set number of assets, which is allocated to the performance obligation discussed above, in its entirety. The Company has determined the date of transfer to the customer to be the date the customer obtains control and title over the asset and the date which revenue is to be recognized and payment is due. As such, there is no impact to the timing and amounts of revenue recognized for equipment sales related to the implementation of ASC 606.

 

Accounting for Leases

 

In February 2016, the FASB issued an accounting standard update that amends the accounting guidance on leases. The intent of this ASU is to increase transparency and comparability among organizations recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements. Lessors will account for leases using an approach that is substantially equivalent to existing U.S. GAAP for sales-type leases, direct financing leases and operating leases. Unlike current guidance, however, a lease with collectability uncertainties may be classified as a sales-type lease. If collectability of lease payments, plus any amount necessary to satisfy a lessee residual value guarantee, is not probable, lease payments received will be recognized as a deposit liability and the underlying assets will not be derecognized until collectability of the remaining amounts becomes probable. The ASU is effective for interim and annual periods beginning after December 15, 2018, with early adoption permitted, and must be adopted using a modified retrospective approach for leases that exist or are entered into after the beginning of the earliest comparative period in the financial statements. The Company plans to adopt this guidance on January 1, 2019, that standard’s effective date, and is currently in the process of determining the impact that the updated accounting guidance will have on the consolidated financial statements and related disclosures. 

 

Classification of Certain Cash Receipts and Cash Payments

 

In August 2016, the FASB issued an accounting standard update that provides guidance on the following eight specific cash flow classification issues: (1) debt prepayment or debt extinguishment costs; (2) settlement of zero-coupon debt instruments or other debt instruments with coupon interest rates that are insignificant in relation to the effective interest rate of the borrowing; (3) contingent consideration payments made after a business combination; (4) proceeds from the settlement of insurance claims; (5) proceeds from the settlement of corporate-owned life insurance policies, including bank-owned life insurance policies; (6) distributions received from equity method investees; (7) beneficial interests in securitization transactions; and (8) separately identifiable cash flows and application of the predominance principle. Current GAAP does not include specific guidance on these eight cash flow classification issues. The amendments of this ASU are effective for reporting periods beginning after December 15, 2017, with early adoption permitted. We will adopt this accounting standard update effective January 1, 2018. The provisions of this update will not have a material impact on our consolidated statements of cash flows. 

 

9 

 

 

Tax Cuts and Jobs Act

 

In February 2018, the FASB issued ASU 2018-02, “Income Statement – Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income” to address stakeholder concerns about the guidance in current U.S. GAAP that requires deferred tax liabilities and assets to be adjusted for the effect of a change in tax laws or rates with the effect included in income from continuing operations in the reporting period that includes the enactment date. The amendments in this Update allow a reclassification from accumulated other comprehensive income to retained earnings for stranded tax effects resulting from the Tax Cuts and Jobs Act. The Company is currently evaluating the timing, methods and impact of adopting this new standard on the consolidated financial statements.

 

NOTE 2 – Acquisitions

 

The Company modified its business plan from building a platform of products in the nutraceutical and dietary supplement space to seeking acquisitions in the healthcare field. HRD identified two target companies for sale that fit their plan going forward of acquiring small, profitable, privately held companies in the healthcare space that generate at least $5 million in revenue and $1 million in EBITDA.

 

On September 29, 2017, the Company finalized a securities purchase agreement with CCI and EZRX to purchase 100% of their outstanding interests for $6.1 million plus 1,751,580 shares of its common stock.

 

The $6.1 million purchase price consists of $3.6 million cash and a $2.5 million 5-year non-interest bearing note, payable at $500,000 per year. Interest on the non-interest bearing note has been imputed using 12.75% interest rate (see Note 4).

 

In accordance with the acquisition method of accounting, the Company allocated the consideration to the net tangible and identifiable intangible assets based on their estimated fair values which were determined by an independent valuation performed by a third party.

 

Goodwill represents the excess of the purchase price over the fair value of the underlying net tangible and identifiable intangible assets.

 

The following table presents the consideration of net assets purchased:

 

Cash  $3,600,000 
1,751,580 shares of common stock issued   175,158 
Note payable   2,500,000 
Imputed interest   (763,558)
Total Purchase Price  $5,511,600 

 

The assets acquired and liabilities assumed as part of our acquisition were recognized at their fair values as of the effective acquisition date, September 29, 2017, based upon an appraisal from a third party. The following table summarizes the fair values assigned to the assets acquired and liabilities assumed.

 

10 

 

 

Cash  $81,359 
Current assets   759,710 
Other non-current assets   11,167 
Intangible assets   4,313,000 
Goodwill   3,313,226 
Current liabilities   (1,343,880)
Deferred tax liability   (1,622,982)
Net assets acquired  $5,511,600 

 

Acquisition costs of $410,000 were incurred and expensed for the year December 31, 2017. As part of the acquisition the company recognized deferred tax liabilities of $1,622,982 related to the unamortized identifiable intangible assets acquired in the amount of $4,313,000 using a blended 37.63% tax rate.

 

The following table provides unaudited pro forma results of operations for the three months ended March 31, 2017 as if the acquisitions had been consummated as of the beginning of that period presented. The pro forma results include the effect of certain purchase accounting adjustments, such as the estimated changes in depreciation and amortization expense on the acquired intangible assets. However, pro forma results do not include any anticipated cost savings or other effects of the planned integration of the companies. Accordingly, such amounts are not necessarily indicative of the results if the acquisition has occurred on the dates indicated, or which may occur in the future.

 

   (Unaudited)
Pro Forma Results
Three months ended March 31,		 
   2017 
     
Revenues  $1,232,278 
Income before income taxes  $82,224 
      
Basic and fully diluted earnings (loss) per share  $0.00 

  

NOTE 3 – Intangible Assets  

 

Amortizing  Estimates  Gross 
Intangible Assets  Useful Life  Carrying Amount 
        
Customer Lists  10 years  $2,653,000 
Tradenames  15 years   377,000 
IP Technologies  10 years   819,000 
Non-compete  5 years   464,000 
       4,313,000 
Less: Accumulated Amortization      (232,566)
         
      $4,080,434 

 

The amortization expense related to the intangible assets was $116,283 and $0 as of March 31, 2018 and 2017, respectively.

 

11 

 

 

The valuation of the assets acquired and liabilities assumed in connection with this acquisition was based on fair values at the acquisition date. The assets purchased and liabilities assumed for these acquisitions have been reflected in the accompanying consolidated balance sheets.

 

NOTE 4 – Notes payable

 

The Company obtained a secured convertible note with a lender for $5 million, interest is payable monthly, at 12.75% per annum, the note matures on September 29, 2020. The note can be converted at any time in whole or in part at $0.44 per share. In addition, the lender received 3,584,279 shares of common stock valued at $0.10 per share along with a 2% original issue discount. The total amount of the discount is $493,345. The Company had incurred $34,917 in loan costs. Both the discount and loan costs are presented as a reduction of the note payable.

 

The Company, as part of consideration for the purchase of CCI and EZRX, obtained a $2.5 million note payable. The note is non-interest bearing with 5 annual payments of $500,000, matures on September 30, 2022. Interest has been imputed at 12.75% per annum. Upon each annual payment date the holder may elect to convert the annual installment of the principal amount due into shares of common stock at $2 per share.

 

   March 31,   December 31, 
   2018   2017 
         
Note payable – monthly interest, 12.75% per annum, matures on September 29, 2020  $5,000,000   $5,000,000 
Less discounts   (411,121)   (452,233)
Note payable – monthly interest, 12.75% per annum, matures on September 30, 2022   2,500,000    2,500,000 
Less discounts   (646,157)   (704,858)
Subtotal   6,442,722    6,342,909 
Less: current portion, net of discount $399,252   265,196    265,196 
Long- term portion  $6,177,526   $6,077,713 
           
Principal payments on the above notes mature as follows:          
Year ending December 31:          
2018  $265,196   $265,196 
2019   301,057    301,057 
2020   5,341,766    5,341,766 
2021   387,980    387,980 
2022   440,443    440,443 
Thereafter  $6,736,442   $6,736,442 

 

12 

 

 

NOTE 5 – Related Party

 

Since inception, the Company has relied in large part on loans from James Pande and David Hopkins, its principal shareholders, to fund its operations.

 

Mr. Pande and Mr. Hopkins advanced money to help fund the Company’s operations. Interest rates ranged from 2.9% - 7.5%, per annum. The balance due as of March 31, 2018 and December 31, 2017 was $0, respectively. The related party loan balance of $33,512 as of December 31, 2017 represents reimbursed expenses owed to shareholder.

 

As of March 31, 2018 and December 31, 2017, the Company has unpaid and accrued salary to its President in the amount of $157,000 and $182,000, respectively.

 

On January 10, 2018, the Company entered into employment agreement with David Hopkins, its President, effective as of January 1, 2018. Pursuant to the employment agreement, Mr. Hopkins assumed the additional position of Chief Executive Officer of the Company. The employment agreement is for an initial term of three (3) and automatically renews for additional three (3) year periods, provided that the Company achieves Adjusted EBITDA (as defined) of $3,500,000 for any calendar year during the initial term and any renewal term.

 

The employment agreement provides for an initial base salary of $175,000. In the event in any calendar year during the initial term or any renewal term, HRD achieves Adjusted EBITDA of $3,500,000, Mr. Hopkins’ annual base salary shall automatically increase to $250,000 and in the event in any calendar year during the initial term or any renewal term, the Company achieves Adjusted EBITDA of $5,000,000, his annual base salary shall automatically increase to $325,000. Mr. Hopkins will also receive a $600 per month car allowance while the employment agreement is in effect.

 

In addition to the foregoing, pursuant to the employment agreement, Mr. Hopkins was granted an option to purchase 525,000 shares of HRD common stock under the Company’s 2015 Stock Incentive Plan at an exercise price of $0.35 per share. The option vests in six equal semi-annual installments commencing June 30, 2018, expires the ten (10) years from the date of grant and is otherwise subject to the terms of the Incentive Plan.

 

NOTE 6 – Stockholders’ Equity

 

The Company has authorized 100,000,000 shares of common stock $.001 par value and 5,000,000 shares of preferred stock $.001 par value.

 

On September 29, 2017, the Company issued 1,751,580 shares of common stock for the purchase of CCI and EZRX (see Note 2). Also, on September 29, 2017, the Company issued 3,584,279 shares of its common stock in connection with its $5 million note (see Note 4).

 

NOTE 7 – 2015 Incentive Stock Plan

 

Our 2015 Incentive Stock Plan (the “Incentive Plan”) provides for equity incentives to be granted to our employees, executive officers or directors or to key advisers or consultants. Equity incentives may be in the form of stock options with an exercise price not less than the fair market value of the underlying shares as determined pursuant to the Incentive Plan, restricted stock awards, other stock based awards, or any combination of the foregoing. The Incentive Plan is administered by the board of directors. 3,000,000 shares of our common stock are reserved for issuance pursuant to the exercise of awards under the Incentive Plan. The number of shares so reserved automatically adjusts upward on January 1 of each year, so that the number of shares covered by the Incentive Plan is equal to 15% of our issued and outstanding common stock. As of March 31, 2018, options to purchase 1,266,666 shares at an exercise price of $0.35 per share have been granted and are outstanding under the Incentive Plan.

 

NOTE 8 – Income Taxes

 

Income tax expense for the three months ended March 31, 2018 and 2017 was $51,029 and $-0-, respectively. The effective tax rates for the three months ended March 31, 2018 and 2017 were 27% and 38.5%, respectively. The 2018 tax rate reflects the enactment of the Tax Cuts and Jobs Act of 2017 (the “Act”) which made significant changes to the Internal Revenue Code. Changes include, but are not limited to, a corporate tax rate decrease from 35% to 21% effective for tax years beginning after December 31, 2017.

 

13 

 

 

As of December 31, 2017, the Company had approximately $566,304 of federal and state net operating loss carryovers (“NOLs”) which begin to expire in 2031.  Utilization of the NOLs may be subject to limitation under the Internal Revenue Code Section 382 should there be a greater than 50% ownership change as determined under regulations.  

 

In assessing the realization of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will be realized.  The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible.  Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies in making this assessment.  Based on the assessment, management has established a full valuation allowance against the entire deferred tax asset relating to NOLs for every period because it is more likely than not that all of the deferred tax asset will not be realized.

 

The Company files U.S. federal and state of Florida and Arkansas tax returns that are subject to audit by tax authorities beginning with the year ended December 31, 2013. The Company’s policy is to classify assessments, if any, for tax and related interest and penalties as tax expense.

 

NOTE 9 – Business Segment Information

 

The Company has two reportable segments (ancillary program and prescription medicine) supported by a corporate group which conducts activities that are non-segment specific. The following table present selected financial information about the Company’s reportable segments for the three months ended March 31, 2018.

 

For the three months 

ended March 31, 2018 

  Consolidated   Ancillary Program   Prescription Medicine   Corporate 
                 
Revenues  $1,924,832   $1,444,060   $480,772   $— 
Cost of Revenue   376,096    —    376,096    — 
Long-lived assets   7,415,872    6,395,764    1,020,108    — 
Income (loss) before income tax   188,996    671,897    95,523    (578,424)
Identifiable assets   4,102,646    3,082,538    1,020,108    — 
Depreciation and amortization   120,179    986    —    119,193 

 

The Company only had one reportable segment for the three months ended March 31, 2017.

  

14 

 

 

NOTE 10 – Subsequent Events

 

The Company has evaluated subsequent events through the date that the financial statements were issued and determined that there were no subsequent events requiring adjustment to or disclosure in the financial statements.

 

15 

 

 

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

 

Unless the context otherwise requires, references in this report to “HRD,” “Health-Right,” “the Company,” “we,” “our” and “us” refers to Health-Right Discoveries, Inc. and its subsidiaries.

 

Forward-Looking Statements

 

Certain statements made in this report are “forward-looking statements” regarding the plans and objectives of management for future operations. Such statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. The forward-looking statements included herein are based on current expectations that involve numerous risks and uncertainties. Our plans and objectives are based, in part, on assumptions involving judgments with respect to, among other things, future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond our control. Although we believe that our assumptions underlying the forward-looking statements are reasonable, any of the assumptions could prove inaccurate and, therefore, there can be no assurance that the forward-looking statements included in this report will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein particularly in view of the current state of our operations, the inclusion of such information should not be regarded as a statement by us or any other person that our objectives and plans will be achieved. We undertake no obligation to revise or update publicly any forward-looking statements for any reason.

 

Historical Background

 

Health-Right was founded as a natural biotech company that seeks to combine science and nutrition to develop branded ingredients, formulations and products that seek to provide a better quality of life for consumers who primarily suffer from stress-induced viruses and diseases. The Company developed a formulation platform by utilizing and scientifically combining various natural ingredients to help positively influence the interrelationship between stress and the immune system. The Company initially applied the formulation platform to Advanced H-Plex Defense Formula 11, its first product (“H-Plex Defense”), an all-natural dietary supplement whose formulation sought to address less than optimal nutrition and nutritional deficiencies to aid persons afflicted with Herpes Simplex Virus 1. Despite test marketing H-Plex Defense through the end of 2014 and positive customer feedback, HRD has been unable to raise sufficient capital to complete development of and commercialize H-Plex Defense.

 

Accordingly, during 2016, the Company shifted its focus to identifying and exploring various opportunities for growth and revenue generation through the acquisition of other products, technologies or companies in the natural biotech, healthcare, nutraceutical and related fields.

 

Business Overview

 

On September 29, 2017, pursuant to a Securities Purchase Agreement dated August 17, 2017, the Company acquired (the “Acquisition”) all the outstanding shares of Common Compounds, Inc.(“CCI”) and all of the outstanding limited liability company interests of EzPharmaRx, LLC (“EZRX”). HRD, through its subsidiaries, CCI and EZRX, along with a licensed pharmaceutical wholesaler, offer and provide their respective services to physician practices that desire to prescribe and dispense certain pharmaceutical products and medications in the practice’s office to patients receiving treatment for work-related injuries (“In-Office Dispensing Services”).

 

CCI offers and provides administrative services and billing services to physician practices (each a “Practice” and collectively, the “Practices”) desiring to make certain over-the-counter products, including non-narcotic topical medications, patches, and creams (“OTC Products”), and certain oral prescription medications (“Oral Medications”) available to patients in the physician practice’s office. Each participating Practice is responsible for obtaining and maintaining any necessary and appropriate licenses, permits, or other documentation required to order, receive, store, and dispense OTC Products or Oral Medications in the Practice’s office in accordance with applicable federal and state law. Such services include, but are not limited to, assisting Practices with insurance claim processing, prior authorization, billing and collections, and recordkeeping. CCI offers its services to Practices participating in the OTC Program and the Full-Formulary Program. CCI also provides billing and collection services on behalf of EZRX in connection with EZRX’s sales and distribution of OTC Products to Practices participating in the OTC Program.

 

16 

 

 

EZRX offers OTC Products to Practices that desire to make such products available to patients in the Practice’s office through participation in the OTC Program. EZRX is not a compounding pharmacy, and neither CCI nor EZRX is involved in creating topicals with compounding pharmacies.

 

Practices participating in the Full-Formulary Program may order and obtain certain Oral Medications directly from a licensed pharmaceutical wholesaler that oversees and manages the sale and distribution of Oral Medications in connection with the Full-Formulary Program.

 

The Acquisition

 

The purchase price for the Acquisition (the “Purchase Price”) consisted of (a) $6,100,000 in cash (the “Cash Purchase Price”); and (b) 1,751,580 “restricted” shares of HRD’s common stock (the “Acquisition Shares”). The Purchase Price was paid at Closing by (a) payment by the Company to the seller of $3,600,000 of the Cash Purchase Price; (b) issuance by the Company to the seller of the Acquisition Shares; and (c) execution and delivery to the seller of a convertible promissory note for the $2,500,000 balance of the Cash Purchase Price (the “CCI Note”).

 

The CCI Note, which does not bear interest, is payable in five equal annual installments of $500,000 on the first, second, third, fourth and fifth anniversaries of the Closing (each a “Due Date”), which installments will be reduced to $377,400 each (with a corresponding reduction in the Cash Purchase Price), if the business fails to meet certain agreed upon financial targets for the years ending December 31, 2017 and 2018. Upon each Due Date, the seller, at his sole option, may elect to convert the annual installment then due under the Note, into shares of Health-Right’s common stock (the “HRD Shares”) at a conversion price equal to 50% of “fair market value,” which is defined as the average closing price for the HRD Shares on the principal market on which they are traded during the thirty (30) trading days prior to the applicable Due Date, provided, further, that (a) the conversion price shall not be lower than $2.00 per HRD Share, subject to adjustment for stock splits, stock dividends and similar recapitalization events; and (b) in the event such conversion price as so adjusted is lower than $2.00 per HRD Share, the installment payable upon such Due Date may not be converted into HRD Shares without written agreement between the Company and the seller.

 

In order to finance the Acquisition, we also entered into a securities purchase agreement with GPB Debt Holdings II, LLC (“GPB”) at Closing (the “GPB Purchase Agreement”). Pursuant to the GPB Purchase Agreement, we sold and issued to GPB a $5,000,000 principal amount senior secured convertible note (the “GPB Note”), for an aggregate purchase price of $4,900,000 (a 2.0% original issue discount). In addition, Health-Right issued to GPB 3,584,279 HRD Shares (the “GPB Shares”).

 

The GPB Note, which matures on the third anniversary of Closing (the “Maturity Date”), provides for monthly payments of interest only, which accrues at the rate of 12.75% per annum. In addition, the GPB Note also provides for an annual payment of paid in kind interest at the rate of 3.0% per annum.

 

The GPB Note (including accrued and unpaid interest) may be prepaid, in whole or in part, so long as a minimum of $500,000 is prepaid each time a repayment is made, at any time prior to the Maturity Date, upon thirty (30) days’ prior written notice; provided, however, that during such notice period, GPB may exercise its conversion rights described below with respect to the portion of the GPB Note to be repaid. Upon a prepayment, in whole or in part, the Company shall pay GPB an additional success fee equal to (a) 2% of any such payment if such payment is paid prior to the first anniversary of Closing; (b) 4% of any such payment if such amount is paid on or after the first anniversary of Closing; and (c) 6% of any such payment if such amount is paid on or after the second anniversary of Closing, but prior to the Maturity Date. 

 

The GPB Note is convertible at any time, in whole or in part, at GPB’s option, into HRD Shares at a conversion price of $0.44 per GPB Share, with customary adjustments for stock splits, stock dividends and other recapitalization events and anti-dilution provisions set forth in the GPB Note, including adjustments in the event the Company sells HRD Shares or HRD Share equivalents at an effective purchase price lower than the conversion price then in effect.

 

17 

 

 

The GPB Note (a) provides for customary affirmative and negative covenants, including restrictions on Health-Right incurring subsequent debt, and (b) contains customary event of default provisions with a default interest rate of the lesser of 17.75% for the cash interest and 8.0% for the paid in-kind interest or the maximum rate permitted by law. Upon the occurrence of an event of default, GPB may require the Company to redeem the GPB Note at 120% of the then outstanding principal balance. The GPB Note is secured by a lien on all of the assets of the Company, including its intellectual property, pursuant to a security agreement entered into between the Company and GPB at Closing (the “Security Agreement”).

 

Corporate Information

 

The Company was incorporated in the state of Florida on October 11, 2011 under the name “Four Plex Partners, Inc.” and changed its name to “Health-Right Discoveries, Inc.” on March 22, 2012.

 

Our executive offices are located at 18851 NE 29th Avenue, Suite 700, Aventura, Florida 33180 and our telephone number is (305) 705-3247. Our corporate website is www.health-right.com. Information appearing on our corporate website is not part of this report.

 

Results of Operations

 

Three months ended March 31, 2018 compared to three months ended March 31, 2017

 

For the three months ended March 31, 2018, we had revenues of $1,924,832, as compared to $-0- for the three months ended March 31, 2017. Revenues in 2018 were wholly generated by the operations of CCI and EZRX subsequent to completion of the Acquisition. Cost of sales was $376,096 for the three months ended March 31, 2018 relating entirely to post-Acquisition operations of CCI and EZRX, as compared to $-0- for the 2017 quarter.

 

General and administrative costs were $1,103,462 for three months ended March 31, 2018, as compared to $18,767 for the three months ended March 31, 2017. This increase is attributable to the significant expansion of the Company’s operations post-Acquisition. Interest expense was $256,278 for the 2018 quarter, as compared to $2,352 for the 2017 quarter. This increase was due in large part to the issuance of notes to the seller and the lender on September 29, 2017, in connection with completing and financing the Acquisition. As a result of the issuance of such notes, it is anticipated that interest expense will increase in future periods.

 

Income tax provision for the three months ended March 31, 2018 was $51,029, as compared to $-0- for the three months ended March 31, 2017.

 

On December 22, 2017, the Tax Cuts and Jobs Act of 2017 (the “Act”) was signed into law, making significant changes to the Internal Revenue Code of 1986, as amended. Changes include, but are not limited to, a corporate tax rate decrease from 35% to 21% effective for tax years beginning after December 31, 2017, the transition of U.S. international taxation from a worldwide tax system to a territorial system, and a one-time transition tax on the mandatory deemed repatriation of cumulative foreign earnings as of December 31, 2017. The Company has calculated the impact of the Act in the year end income tax provision in accordance with management’s understanding of the Act and guidance available as of the date of this report. The income tax benefit of $7,947 for the three months ended March 31, 2017 was fully reserved.

 

The Company had net income for the three months ended March 31, 2018 of $137,967, as compared to a net loss of $21,119 for the three months ended March 31, 2017. The change from net loss in the 2017 quarter to net income in the 2018 quarter, was entirely due to post-Acquisition operations of CCI and EZRX.

 

Liquidity and Capital Resources

 

As of March 31, 2018, total assets were $9,711,133, as compared to $9,483,169 on December 31, 2017, with the increase attributable to expanded business operations. Total current liabilities as of March 31, 2018 were $1,766,180, as compared to $1,827,025 as of December 31, 2017 and as of March 31, 2018 and December 31, 2017, the Company had long-term liabilities of $7,208,767 and $7,057,925, respectively. The increase changes in the foregoing were due in large part to the accrual of interest on notes issued to the lender on September 29, 2017.

 

18 

 

 

Net cash provided by operating activities increased to $371,163 for the three months ended March 31, 2018, as compared to net cash used in operating activities of $22,439 in the 2017 quarter, resulting from cash generated by the post-Acquisition operations of CCI and EZRX.

 

Net cash used in investing activities was $12,607 for the three months ended March 31, 2018, as compared to $-0- for the three months ended March 31, 2017, reflecting purchases of property and equipment in the 2018 quarter.

 

Net cash used in financing activities was $33,512 for the three months ended March 31, 2018, representing the repayment of shareholder loans by the Company during the 2018 quarter. Net cash provided by financing activities for the three months ended March 31. 2017 was $4,334, representing the proceeds from shareholder loans to the Company during the 2017 quarter.

 

Prior to completion of the Acquisition, our primary sources of capital to develop and implement our business plan were private placements of our securities and shareholder loans.

 

In order to finance the Acquisition, at Closing, we entered into the GPB Purchase Agreement with GPB, pursuant to which we sold and issued to GPB the $5,000,000 principal amount GPB Note for an aggregate purchase price of $4,900,000 (a 2.0% original issue discount). In addition, Health-Right issued to GPB the 3,584,279 GPB Shares.

 

The GPB Note, which matures on the Maturity Date (the third anniversary of issuance, provides for monthly payments of interest only, which accrues at the rate of 12.75% per annum. In addition, the GPB Note also provides for an annual payment of paid in kind interest at the rate of 3.0% per annum.

 

The GPB Note (including accrued and unpaid interest) may be prepaid, in whole or in part, so long as a minimum of $500,000 is prepaid each time a repayment is made, at any time prior to the Maturity Date, upon thirty (30) days’ prior written notice; provided, however, that during such notice period, GPB may exercise its conversion rights described below with respect to the portion of the GPB Note to be repaid. Upon a prepayment, in whole or in part, the Company shall pay GPB an additional success fee equal to (a) 2% of any such payment if such payment is paid prior to the first anniversary of issuance; (b) 4% of any such payment if such amount is paid on or after the first anniversary of issuance; and (c) 6% of any such payment if such amount is paid on or after the second anniversary of issuance, but prior to the Maturity Date.

 

The GPB Note is convertible at any time, in whole or in part, at GPB’s option, into HRD Shares at a conversion price of $0.44 per GPB Share, with customary adjustments for stock splits, stock dividends and other recapitalization events and anti-dilution provisions set forth in the GPB Note, including adjustments in the event the Company sells HRD Shares or HRD Share equivalents at an effective purchase price lower than the conversion price then in effect.

 

The GPB Note (a) provides for customary affirmative and negative covenants, including restrictions on Health-Right incurring subsequent debt, and (b) contains customary event of default provisions with a default interest rate of the lesser of 17.75% for the cash interest and 8.0% for the paid in-kind interest or the maximum rate permitted by law. Upon the occurrence of an event of default, GPB may require the Company to redeem the GPB Note at 120% of the then outstanding principal balance. The GPB Note is secured by a lien on all of the assets of the Company, including its intellectual property, pursuant to the Security Agreement entered into between the Company and GPB at Closing.

 

There can be no assurance that, notwithstanding completion of the Acquisition, that the Company will not require additional financing to achieve sustained profitability. While we believe additional financing will be available to us, if required, there can be no assurance that equity or debt financing will be available on commercially reasonable terms or otherwise, when, as and if needed. Moreover, any such additional financing may dilute the interests of existing shareholders. The absence of additional financing, when needed, could substantially harm the Company, its business, results of operations and financial condition.

 

19 

 

 

Critical Accounting Policies

 

Revenue Recognition

 

The Company follows the guidance of the Accounting Standards Codification (“ASC”) Topic 605, “Revenue Recognition.” We record revenue when persuasive evidence of an arrangement exists, product delivery has occurred, the selling price to the customer is fixed or determinable and collectability of the revenue is reasonably assured. The Company has not experienced any significant returns from customers and accordingly, in management’s opinion, no reserve for returns has been provided.

 

CCI’s revenue results from the consulting services agreements, which included providing services to physicians for billing insurance companies. CCI remits billings to insurance companies on behalf of the physicians, collect the proceeds and remits an agreed upon percentage amount to the physician. The amounts reported as revenue are net of amounts remitted. The Company accounts for this revenue in accordance with Staff Accounting Bulletin (“SAB”) No. 104, which states that the revenue is not earned until the company has been paid by the insurance company at which time it becomes realized or realizable.

 

EZRX’s revenue from the sale of products are recognized when the sale is consummated and title is transferred.

 

Intangible Assets

 

Intangible assets consist primarily of the Tradenames, IP Technologies, Customer list, and a Non-compete agreement resulting from the acquisition referred to in Note 3. These intangible assets have finite lives and are amortized over the periods in which they provide benefit. The Company assesses the impairment of long-lived assets, including identifiable intangible assets subject to amortization, whenever significant events or significant changes in circumstances indicate the carrying value may not be recoverable. Intangible assets with indefinite lives, are subject to impairment testing in accordance with accounting standards governing such on an annual basis, or more frequently if an event or change in circumstances indicates that the fair value of a reporting unit has been reduced below its carrying value. See Note 3 for acquisition to the consolidated financial statements for disclosure on intangible assets. 

 

Use of Estimates

 

The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.  Actual results could differ from those estimates.  Significant estimates included deferred revenue, costs incurred related to deferred revenue, the useful lives of property and equipment, the useful lives of intangible assets and accounting for the business combination.

 

Income Taxes

 

The Company accounts for income taxes in accordance with ASC 740, Accounting for Income Taxes, as clarified by ASC 740-10, Accounting for Uncertainty in Income Taxes.  Under this method, deferred income taxes are determined based on the estimated future tax effects of differences between the financial statement and tax basis of assets and liabilities given the provisions of enacted tax laws.  Deferred income tax provisions and benefits are based on changes to the assets or liabilities from year to year.  In providing for deferred taxes, the Company considers tax regulations of the jurisdictions in which the Company operates, estimates of future taxable income, and available tax planning strategies.  If tax regulations, operating results or the ability to implement tax-planning strategies vary, adjustments to the carrying value of deferred tax assets and liabilities may be required.  Valuation allowances are recorded related to deferred tax assets based on the “more likely than not” criteria of ASC 740.

 

ASC 740-10 requires that the Company recognize the financial statement benefit of a tax position only after determining that the relevant tax authority would more likely than not sustain the position following an audit.  For tax positions meeting the “more-likely-than-not” threshold, the amount recognized in the financial statements is the largest benefit that has a greater than 50 percent likelihood of being realized upon ultimate settlement with the relevant tax authority.

 

20 

 

 

Off-Balance Sheet Arrangements

 

There are no off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that is material to investors.

 

Item 3. Quantitative Disclosures About Market Risks.

 

As a “smaller reporting company,” we are not required to provide the information required by this Item.

 

Item 4. Controls and Procedures.

 

Management’s Report on Disclosure Controls and Procedures

 

Our President and Chief Executive Officer, as our sole executive officer, conducted an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934 (the “Exchange Act”), as amended, as of March 31, 2018, to ensure that information required to be disclosed by us in the reports filed or submitted by us under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the rules and forms adopted by the Securities and Exchange Commission (the “SEC”), including to ensure that information required to be disclosed by us in the reports filed or submitted by us under the Exchange Act is accumulated and communicated to our management, including our President, as our Principal Executive, Financial and Accounting Officer, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. Based on that evaluation, our President has concluded that as of March 31, 2018, our disclosure controls and procedures were not effective at the reasonable assurance level due to the material weaknesses identified and described in Item 9A(b) of our Annual Report on Form 10-K for the year ended December 31, 2017.

 

Our President and Chief Executive Officer, as our sole executive officer, does not expect that our disclosure controls or internal controls will prevent all error and all fraud. Although our disclosure controls and procedures were designed to provide reasonable assurance of achieving their objectives and our principal executive officer has determined that our disclosure controls and procedures are effective at doing so, a control system, no matter how well conceived and operated, can provide only reasonable, not absolute assurance that the objectives of the system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within the Company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented if there exists in an individual a desire to do so. There can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions.

 

Changes in Internal Controls Over Financial Reporting

 

There were no changes in our internal controls over financial reporting that occurred during the period covered by this report that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

 

21 

 

 

PART II - OTHER INFORMATION

 

Item 1. Legal Proceedings.

 

We know of no material, existing or pending legal proceedings against our company, nor are we involved as a plaintiff in any material proceeding or pending litigation. There are no proceedings in which any of our directors, officers or affiliates, or any registered or beneficial shareholder, is an adverse party or has a material interest adverse to our interest.

 

Item 1A. Risk Factors.

 

As a “smaller reporting company,” we are not required to provide the information required by this Item.

 

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

 

None.

 

Item 4. Mine Safety Disclosures.

 

Not applicable.

 

Item 5. Other Information.

 

None.

 

Item 6. Exhibits.

 

Exhibit
Number		   Description of Exhibit
     
31.1   Section 302 Certification
32.1   Section 906 Certification

 

22 

 

 

SIGNATURES 

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

  HEALTH-RIGHT DISCOVERIES, INC.
   
Dated: May 11, 2018 By:  /s/ David Hopkins
    David Hopkins, President and Chief Executive Officer
    (Principal Executive, Financial and Accounting Officer)

 

23 

 EX-31.1 2 s110106_ex31-1.htm EXHIBIT 31.1

 

Exhibit 31.1

 

CERTIFICATION OF CHIEF EXECUTIVE OFFICER 

AND CHIEF FINANCIAL OFFICER PURSUANT TO 

18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO 

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

 

I, David Hopkins, Chief Executive Officer and Chief Financial Officer of Health-Right Discoveries, Inc., a Florida corporation (the “Registrant”), certify that:

 

1.            I have reviewed this Form 10-Q for the quarter ended March 31, 2018 of the Registrant;

 

2.            Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3.            Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Registrant as of, and for, the periods presented in this report;

 

4.            I, as the Registrant’s sole executive officer, am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e)and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15 (f) and 15d-15(f)) for the registrant and have:

 

  a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under my supervision, to ensure that material information relating to the Registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

  b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under my supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

  c) Evaluated the effectiveness of the Registrant’s disclosure controls and procedures and presented in this report my conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

  d) Disclosed in this report any change in the Registrant’s internal control over financial reporting that occurred during the Registrant’s most recent fiscal quarter (the Registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Registrant’s internal control over financial reporting; and

 

5.            I, as the Registrant’s sole officer, have disclosed, based on my most recent evaluation of internal control over financial reporting, to the Registrant’s auditors and the audit committee of the Registrant’s board of directors (or persons performing the equivalent functions):

 

  a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Registrant’s ability to record, process, summarize and report financial information; and

 

 

 

   

  b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the Registrant’s internal control over financial reporting.

 

Date: May 11, 2018  
     
HEALTH-RIGHT DISCOVERIES, INC.  
     
By:  /s/ David Hopkins  
 

David Hopkins, President and Chief Executive

Officer (Principal Executive, Financial and

Accounting Officer)

  

 

 

 EX-32.1 3 s110106_ex32-1.htm EXHIBIT 32.1

  

Exhibit 32.1

 

CERTIFICATION OF CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER 

PURSUANT TO 18 U.S.C. SECTION 1350 AS ADOPTED 

PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Quarterly Report of Health-Right Discoveries Inc., a Florida corporation (the “Company”) on Form 10-Q for the quarter ended March 31, 2018, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, David Hopkins, the Chief Executive Officer and Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that:

 

  1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

  2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Date: May 11, 2018      
       
  HEALTH-RIGHT DISCOVERIES, INC  
       
  By:   /s/ David Hopkins  
    President and Chief Executive Officer  
    (Principal Executive, Financial and Accounting Officer)  

 

 

 

 EX-101.INS 4 cik0001537663-20180331.xml XBRL INSTANCE FILE 0001537663 2018-01-01 2018-03-31 0001537663 2016-12-31 0001537663 2018-04-14 0001537663 2018-03-31 0001537663 2017-12-31 0001537663 2017-01-01 2017-03-31 0001537663 2017-03-31 0001537663 cik0001537663:CommonCompoundsIncAndEzPharmaRxLLCMember 2017-09-29 0001537663 cik0001537663:CommonCompoundsIncAndEzPharmaRxLLCMember 2017-09-01 2017-09-29 0001537663 2017-01-01 2017-12-31 0001537663 us-gaap:CustomerListsMember 2018-01-01 2018-03-31 0001537663 us-gaap:TradeNamesMember 2018-01-01 2018-03-31 0001537663 us-gaap:PatentedTechnologyMember 2018-01-01 2018-03-31 0001537663 us-gaap:NoncompeteAgreementsMember 2018-01-01 2018-03-31 0001537663 us-gaap:CustomerListsMember 2018-03-31 0001537663 us-gaap:TradeNamesMember 2018-03-31 0001537663 us-gaap:PatentedTechnologyMember 2018-03-31 0001537663 us-gaap:NoncompeteAgreementsMember 2018-03-31 0001537663 cik0001537663:NotesPayableOneMember 2018-03-31 0001537663 cik0001537663:NotesPayableTwoMember 2018-03-31 0001537663 cik0001537663:NotesPayableOneMember 2017-12-31 0001537663 cik0001537663:NotesPayableTwoMember 2017-12-31 0001537663 cik0001537663:LenderMember 2017-09-29 0001537663 cik0001537663:LenderMember 2017-09-01 2017-09-29 0001537663 cik0001537663:CommonCompoundsIncAndEzPharmaRxLLCMember cik0001537663:SellerMember 2017-09-29 0001537663 cik0001537663:CommonCompoundsIncAndEzPharmaRxLLCMember cik0001537663:LenderMember 2017-09-29 0001537663 cik0001537663:StockOptionIncentivePlan2015Member 2018-01-01 2018-03-31 0001537663 cik0001537663:StockOptionIncentivePlan2015Member 2018-03-31 0001537663 us-gaap:DirectorMember us-gaap:SecuredDebtMember srt:MinimumMember 2018-03-31 0001537663 us-gaap:DirectorMember us-gaap:SecuredDebtMember srt:MaximumMember 2018-03-31 0001537663 us-gaap:PresidentMember 2018-01-01 2018-01-10 0001537663 us-gaap:PresidentMember 2018-03-31 0001537663 us-gaap:PresidentMember 2017-12-31 0001537663 us-gaap:DirectorMember us-gaap:SecuredDebtMember 2018-03-31 0001537663 us-gaap:DirectorMember us-gaap:SecuredDebtMember 2017-12-31 0001537663 cik0001537663:ShareholderMember 2017-01-01 2017-12-31 0001537663 2017-10-01 2017-12-31 0001537663 cik0001537663:AncillaryProgramMember 2018-01-01 2018-03-31 0001537663 cik0001537663:PrescriptionMedicineMember 2018-01-01 2018-03-31 0001537663 us-gaap:CorporateMember 2018-01-01 2018-03-31 0001537663 cik0001537663:AncillaryProgramMember 2018-03-31 0001537663 cik0001537663:PrescriptionMedicineMember 2018-03-31 0001537663 us-gaap:CorporateMember 2018-03-31 0001537663 us-gaap:PresidentMember 2018-01-01 2018-03-31 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure cik0001537663:Number 2018 Q1 Smaller Reporting Company Yes No No false 2018-03-31 10-Q 0001537663 Health-Right Discoveries, Inc. --12-31 22869191 22869191 3584279 1751580 3584279 22869191 4080434 4196717 22212 10592 265196 265196 6177526 6077713 399252 399252 493345 100000000 100000000 0.001 0.001 5000000 5000000 0.001 0.001 51029 0 1924832 1444060 480772 376096 376096 188996 -21119 671897 95523 -578424 9711133 9483169 3313226 3313226 2295261 1962634 30219 32580 481056 471112 18373 1783986 1458942 278 1766180 1827025 157000 182000 33512 1343984 1346317 7208767 7057925 1031241 980212 8974947 8884950 9711133 9483169 736186 598219 -404650 -542617 1117967 1117967 22869 22869 658026 757829 0 0 0 0 22869191 22869191 22869191 17533332 0.01 -0.00 137967 -21119 1359740 21119 256278 2352 1103462 18767 1548736 99813 116283 986 -9944 51029 371163 -22439 2352 -2332 -12607 325044 -18095 -33512 4344 33512 4344 159374 2361 -16672 12607 P7Y 31801 19195 9589 8603 0 0 3600000 175158 2500000 -763558 5511600 81359 759710 11167 4313000 1343880 1622982 1232278 82224 0.00 410000 6100000 1751580 3600000 2500000 500000 0.1275 0.3763 P10Y P15Y P10Y P5Y 4313000 2653000 377000 819000 464000 232566 5000000 2500000 5000000 2500000 399252 399252 411121 646157 452233 704858 6442722 6342909 34917 265196 265196 301057 301057 5341766 5341766 387980 387980 440443 440443 6736442 6736442 2500000 5000000 0.1275 2022-09-30 2020-09-29 2.00 0.10 2500000 0.1275 5000000 3000000 1266666 0.35 0.35 0.029 0.075 0 0 33512 157000 182000 0.27 0.385 566304 2031-12-31 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Utilization of the NOLs may be subject to limitation under the Internal Revenue Code Section 382 should there be a greater than 50% ownership change as determined under regulations.&#160;&#160;</p> 0.21 7415872 6395764 1020108 4102646 3082538 1020108 120179 986 119193 1 -25000 13000 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 2 &#8211; Acquisitions</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company modified its business plan from building&#160;a platform of products in the&#160;nutraceutical and dietary supplement space to seeking acquisitions in the healthcare field. HRD identified two target companies for sale that fit their plan going forward of acquiring small, profitable, privately held companies in the healthcare space that generate at least $5 million in revenue and $1 million in EBITDA.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On September 29, 2017, the Company finalized a securities purchase agreement with CCI and EZRX to purchase 100% of their outstanding interests for $6.1 million plus 1,751,580 shares of its common stock.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In accordance with the acquisition method of accounting, the Company allocated the consideration to the net tangible and identifiable intangible assets based on their estimated fair values which were determined by an independent valuation performed by a third party.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Goodwill represents the excess of the purchase price over the fair value of the underlying net tangible and identifiable intangible assets.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table presents the consideration of net assets purchased:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 81%; text-align: justify"><font style="font-size: 10pt">Cash</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 16%; text-align: right"><font style="font-size: 10pt">3,600,000</font></td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">1,751,580 shares of common stock issued</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">175,158</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify"><font style="font-size: 10pt">Note payable</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">2,500,000</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1pt; text-align: justify"><font style="font-size: 10pt">Imputed interest</font></td> <td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: black 1pt solid">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">(763,558</font></td> <td style="padding-bottom: 1pt"><font style="font-size: 10pt">)</font></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt; text-align: justify"><font style="font-size: 10pt">Total Purchase Price</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">5,511,600</font></td> <td style="padding-bottom: 2.5pt">&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The assets acquired and liabilities assumed as part of our acquisition were recognized at their fair values as of the effective acquisition date, September 29, 2017, based upon an appraisal from a third party. The following table summarizes the fair values assigned to the assets acquired and liabilities assumed.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 81%; padding-left: 5.4pt; text-align: justify"><font style="font-size: 10pt">Cash</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 16%; text-align: right"><font style="font-size: 10pt">81,359</font></td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 5.4pt; text-align: justify"><font style="font-size: 10pt">Current assets</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">759,710</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 5.4pt; text-align: justify"><font style="font-size: 10pt">Other non-current assets</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">11,167</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 5.4pt; text-align: justify"><font style="font-size: 10pt">Intangible assets</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">4,313,000</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 5.4pt; text-align: justify"><font style="font-size: 10pt">Goodwill</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">3,313,226</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 5.4pt; text-align: justify"><font style="font-size: 10pt">Current liabilities</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">(1,343,880</font></td> <td><font style="font-size: 10pt">)</font></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1pt; padding-left: 5.4pt; text-align: justify"><font style="font-size: 10pt">Deferred tax liability</font></td> <td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: black 1pt solid">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">(1,622,982</font></td> <td style="padding-bottom: 1pt"><font style="font-size: 10pt">)</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt; padding-left: 5.4pt; text-align: justify"><font style="font-size: 10pt">Net assets acquired</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">5,511,600</font></td> <td style="padding-bottom: 2.5pt">&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Acquisition costs of $410,000 were incurred and expensed for the year December 31, 2017. As part of the acquisition the company recognized deferred tax liabilities of $1,622,982 related to the unamortized identifiable intangible assets acquired in the amount of $4,313,000 using a blended 37.63% tax rate.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">The following table provides unaudited pro forma results of operations for the three months ended March 31, 2017 as if the acquisitions had been consummated as of the beginning of that period presented. The pro forma results include the effect of certain purchase accounting adjustments, such as the estimated changes in depreciation and amortization expense on the acquired intangible assets. However, pro forma results do not include any anticipated cost savings or other effects of the planned integration of the companies. Accordingly, such amounts are not necessarily indicative of the results if the acquisition has occurred on the dates indicated, or which may occur in the future.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: center"><font style="font-size: 10pt">(Unaudited) </font><br /> <font style="font-size: 10pt">Pro Forma Results </font><br /> <font style="font-size: 10pt">Three months ended March 31,</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: center"><font style="font-size: 10pt">2017</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: center">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 87%; padding-bottom: 2.5pt"><font style="font-size: 10pt">Revenues</font></td> <td style="width: 1%; padding-bottom: 2.5pt">&#160;</td> <td style="width: 1%; border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="width: 10%; border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">1,232,278</font></td> <td style="width: 1%; padding-bottom: 2.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">Income before income taxes</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">82,224</font></td> <td style="padding-bottom: 2.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">Basic and fully diluted earnings (loss) per share</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">0.00</font></td> <td style="padding-bottom: 2.5pt">&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 3 &#8211; Intangible Assets &#160;</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center"><font style="font-size: 10pt"><b>Amortizing</b></font></td> <td>&#160;</td> <td style="text-align: center"><font style="font-size: 10pt"><b>Estimates</b></font></td> <td>&#160;</td> <td colspan="2" style="text-align: center"><font style="font-size: 10pt"><b>Gross</b></font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt"><b>Intangible Assets</b></font></td> <td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt"><b>Useful Life</b></font></td> <td style="padding-bottom: 1pt">&#160;</td> <td nowrap="nowrap" colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt"><b>Carrying Amount</b></font></td> <td style="padding-bottom: 1pt">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">&#160;</td> <td>&#160;</td> <td style="text-align: justify">&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: justify">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 74%; text-align: justify"><font style="font-size: 10pt">Customer Lists</font></td> <td style="width: 1%">&#160;</td> <td style="width: 12%; padding-left: 5.4pt; text-align: justify"><font style="font-size: 10pt">10 years</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 10%; text-align: right"><font style="font-size: 10pt">2,653,000</font></td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify"><font style="font-size: 10pt">Tradenames</font></td> <td>&#160;</td> <td style="padding-left: 5.4pt; text-align: justify"><font style="font-size: 10pt">15 years</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">377,000</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify"><font style="font-size: 10pt">IP Technologies</font></td> <td>&#160;</td> <td style="padding-left: 5.4pt; text-align: justify"><font style="font-size: 10pt">10 years</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">819,000</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1pt; text-align: justify"><font style="font-size: 10pt">Non-compete</font></td> <td style="padding-bottom: 1pt">&#160;</td> <td style="padding-bottom: 1pt; padding-left: 5.4pt; text-align: justify"><font style="font-size: 10pt">5 years</font></td> <td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: black 1pt solid">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">464,000</font></td> <td style="padding-bottom: 1pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify">&#160;</td> <td>&#160;</td> <td style="padding-left: 5.4pt; text-align: justify">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">4,313,000</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1pt; text-align: justify"><font style="font-size: 10pt">Less: Accumulated Amortization</font></td> <td style="padding-bottom: 1pt">&#160;</td> <td style="padding-bottom: 1pt; padding-left: 5.4pt; text-align: justify">&#160;</td> <td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: black 1pt solid">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">(232,566</font></td> <td style="padding-bottom: 1pt"><font style="font-size: 10pt">)</font></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify">&#160;</td> <td>&#160;</td> <td style="padding-left: 5.4pt; text-align: justify">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt; text-align: justify">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt; padding-left: 5.4pt; text-align: justify">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">4,080,434</font></td> <td style="padding-bottom: 2.5pt">&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The amortization expense related to the intangible assets was $116,283 and $0 as of March 31, 2018 and 2017, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The valuation of the assets acquired and liabilities assumed in connection with this acquisition was based on fair values at the acquisition date. The assets purchased and liabilities assumed for these acquisitions have been reflected in the accompanying consolidated balance sheets.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 4 &#8211; Notes payable </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company obtained a secured convertible note with a lender for $5 million, interest is payable monthly, at 12.75% per annum, the note matures on September 29, 2020. The note can be converted at any time in whole or in part at $0.44 per share. In addition, the lender received 3,584,279 shares of common stock valued at $0.10 per share along with a 2% original issue discount. The total amount of the discount is $493,345. The Company had incurred $34,917 in loan costs. Both the discount and loan costs are presented as a reduction of the note payable.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company, as part of consideration for the purchase of CCI and EZRX, obtained a $2.5 million note payable. The note is non-interest bearing with 5 annual payments of $500,000, matures on September 30, 2022. Interest has been imputed at 12.75% per annum. Upon each annual payment date the holder may elect to convert the annual installment of the principal amount due into shares of common stock at $2 per share.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: center"><font style="font-size: 10pt">March 31,</font></td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: center"><font style="font-size: 10pt">December 31,</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: right">&#160;</td> <td style="padding-bottom: 1pt">&#160;</td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt">2018</font></td> <td style="padding-bottom: 1pt">&#160;</td> <td style="padding-bottom: 1pt">&#160;</td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt">2017</font></td> <td style="padding-bottom: 1pt">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 74%"><font style="font-size: 10pt">Note payable &#8211; monthly interest, 12.75% per annum, matures on September 29, 2020</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 10%; text-align: right"><font style="font-size: 10pt">5,000,000</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 10%; text-align: right"><font style="font-size: 10pt">5,000,000</font></td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Less discounts</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">(411,121</font></td> <td><font style="font-size: 10pt">)</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">(452,233</font></td> <td><font style="font-size: 10pt">)</font></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Note payable &#8211; monthly interest, 12.75% per annum, matures on September 30, 2022</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">2,500,000</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">2,500,000</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1pt"><font style="font-size: 10pt">Less discounts</font></td> <td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: black 1pt solid">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">(646,157</font></td> <td style="padding-bottom: 1pt"><font style="font-size: 10pt">)</font></td> <td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: black 1pt solid">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">(704,858</font></td> <td style="padding-bottom: 1pt"><font style="font-size: 10pt">)</font></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Subtotal</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">6,442,722</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">6,342,909</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1pt"><font style="font-size: 10pt">Less: current portion, net of discount $399,252</font></td> <td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: black 1pt solid">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">265,196</font></td> <td style="padding-bottom: 1pt">&#160;</td> <td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: black 1pt solid">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">265,196</font></td> <td style="padding-bottom: 1pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">Long- term portion</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">6,177,526</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">6,077,713</font></td> <td style="padding-bottom: 2.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Principal payments on the above notes mature as follows:</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: right"><font style="font-size: 10pt">Year ending December 31:</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: right"><font style="font-size: 10pt">2018</font></td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">265,196</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">265,196</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: right"><font style="font-size: 10pt">2019</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">301,057</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">301,057</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: right"><font style="font-size: 10pt">2020</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">5,341,766</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">5,341,766</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: right"><font style="font-size: 10pt">2021</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">387,980</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">387,980</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1pt; text-align: right"><font style="font-size: 10pt">2022</font></td> <td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: black 1pt solid">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">440,443</font></td> <td style="padding-bottom: 1pt">&#160;</td> <td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: black 1pt solid">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">440,443</font></td> <td style="padding-bottom: 1pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt; text-align: right"><font style="font-size: 10pt">Thereafter</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">6,736,442</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">6,736,442</font></td> <td style="padding-bottom: 2.5pt">&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 6 &#8211; Stockholders&#8217; Equity</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company has authorized 100,000,000 shares of common stock $.001 par value and 5,000,000 shares of preferred stock $.001 par value.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On September 29, 2017, the Company issued 1,751,580 shares of common stock for the purchase of CCI and EZRX (see Note 2). Also, on September 29, 2017, the Company issued 3,584,279 shares of its common stock in connection with its $5 million note (see Note 4).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 8 &#8211; Income Taxes</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Income tax expense for the three months ended March&#160;31, 2018 and 2017 was $51,029 and $-0-, respectively. The effective tax rates for the three months ended March 31, 2018 and 2017 were 27% and 38.5%, respectively. The 2018 tax rate reflects the enactment of the Tax Cuts and Jobs Act of 2017 (the &#8220;Act&#8221;) which made significant changes to the Internal Revenue Code. Changes include, but are not limited to, a corporate tax rate decrease from 35% to 21% effective for tax years beginning after December 31, 2017.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of December 31, 2017, the Company had approximately $566,304 of federal and state net operating loss carryovers (&#8220;NOLs&#8221;) which begin to expire in 2031.&#160;&#160;Utilization of the NOLs may be subject to limitation under the Internal Revenue Code Section 382 should there be a greater than 50% ownership change as determined under regulations.&#160;&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In assessing the realization of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will be realized.&#160;&#160;The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible.&#160;&#160;Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies in making this assessment.&#160;&#160;Based on the assessment, management has established a full valuation allowance against the entire deferred tax asset relating to NOLs for every period because it is more likely than not that all of the deferred tax asset will not be realized.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company files U.S. federal and state of Florida and Arkansas tax returns that are subject to audit by tax authorities beginning with the year ended December 31, 2013. The Company&#8217;s policy is to classify assessments, if any, for tax and related interest and penalties as tax expense.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 9 &#8211; Business Segment Information </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has two reportable segments (ancillary program and prescription medicine) supported by a corporate group which conducts activities that are non-segment specific. The following table present selected financial information about the Company&#8217;s reportable segments for the three months ended March 31, 2018.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>For&#160;the&#160;three months</b>&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>ended&#160;March 31,&#160;2018</b>&#160;</p></td> <td style="padding-bottom: 1pt">&#160;</td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt"><b>Consolidated</b></font></td> <td style="padding-bottom: 1pt">&#160;</td> <td style="padding-bottom: 1pt">&#160;</td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt"><b>Ancillary Program</b></font></td> <td style="padding-bottom: 1pt">&#160;</td> <td style="padding-bottom: 1pt">&#160;</td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt"><b>Prescription Medicine</b></font></td> <td style="padding-bottom: 1pt">&#160;</td> <td style="padding-bottom: 1pt">&#160;</td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt"><b>Corporate</b></font></td> <td style="padding-bottom: 1pt">&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 48%"><font style="font-size: 10pt">Revenues</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 10%; text-align: right"><font style="font-size: 10pt">1,924,832</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 10%; text-align: right"><font style="font-size: 10pt">1,444,060</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 10%; text-align: right"><font style="font-size: 10pt">480,772</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 10%; text-align: right"><font style="font-size: 10pt">&#8212;</font></td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Cost of Revenue</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">376,096</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">&#8212;</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">376,096</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">&#8212;</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Long-lived assets</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">7,415,872</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">6,395,764</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">1,020,108</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">&#8212;</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Income (loss) before income tax</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">188,996</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">671,897</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">95,523</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">(578,424</font></td> <td><font style="font-size: 10pt">)</font></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Identifiable assets</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">4,102,646</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">3,082,538</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">1,020,108</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">&#8212;</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Depreciation and amortization</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">120,179</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">986</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">&#8212;</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">119,193</font></td> <td>&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company only had one reportable segment for the three months ended March 31, 2017.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 10 &#8211; Subsequent Events</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has evaluated subsequent events through the date that the financial statements were issued and determined that there were no subsequent events requiring adjustment to or disclosure in the financial statements.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><i>Basis of Presentation</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in conformity with accounting principles generally accepted in the United States (&#8220;GAAP&#8221;) for interim financial information and in accordance with the rules and regulations of the Securities and Exchange Commission.&#160; Therefore, they do not include all information and footnotes normally included in annual consolidated financial statements and should be read in conjunction with the consolidated financial statement and notes thereto included in the 2017 Form 10-K for the year ended December 31, 2017. In the opinion of the Company&#8217;s management, the accompanying unaudited condensed consolidated financial statements contain all the adjustments necessary (consisting only of normal recurring accruals) to present the financial position of the Company as of March 31, 2018 and the results of operations and cash flows for the periods presented. The results of operations for the three months ended March 31, 2018 are not necessarily indicative of the operating results for the full fiscal year or any future period.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><i>Use of Estimates</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">The preparation of the financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements and the reported amounts of revenue and expenses during the reporting periods. Actual results could differ from those estimates. Certain of the Company&#8217;s estimates could be affected by external conditions, including those unique to its industry, and general economic conditions. It is possible that these external factors could have an effect on the Company&#8217;s estimates that could cause actual results to differ from its estimates. The Company re-evaluates all of its accounting estimates at least quarterly based on these conditions and record adjustments when necessary.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><i>Inventories</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Inventories, which consist of the Company&#8217;s product held for resale, are stated at the lower of cost, determined using the first-in, first-out, or net realizable value. Net realizable value is the estimated selling price, in the ordinary course of business, less estimated costs to complete and dispose of the product.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">If the Company identifies excess, obsolete or unsalable items, its inventories are written down to their realizable value in the period in which the impairment is first identified. Shipping and handling costs incurred for inventory purchases and product shipments are recorded in cost of sales in the Company&#8217;s statements of operations. In the first quarter of 2018 and 2017, the Company recorded a loss of $-0- due to management&#8217;s estimate of obsolete inventory.&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><i>Property and Equipment</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white; text-align: justify">Property and equipment are stated at cost. Expenditures for additions are capitalized, repairs and maintenance are expensed as incurred. Depreciation is provided using the straight-line method over the estimated useful lives of the assets, which are as follows:&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: justify">&#160;</td> <td style="padding-bottom: 1pt">&#160;</td> <td nowrap="nowrap" colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt">March 31, 2018</font></td> <td style="padding-bottom: 1pt">&#160;</td> <td style="padding-bottom: 1pt">&#160;</td> <td nowrap="nowrap" colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt">December 31, 2017</font></td> <td style="padding-bottom: 1pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 74%; text-align: justify"><font style="font-size: 10pt">Machinery and equipment &#8211; 7 years</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 10%; text-align: right"><font style="font-size: 10pt">31,801</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 10%; text-align: right"><font style="font-size: 10pt">19,195</font></td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1pt; text-align: justify"><font style="font-size: 10pt">Accumulated depreciation</font></td> <td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: black 1pt solid">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">(9,589</font></td> <td style="padding-bottom: 1pt"><font style="font-size: 10pt">)</font></td> <td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: black 1pt solid">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">(8,603</font></td> <td style="padding-bottom: 1pt"><font style="font-size: 10pt">)</font></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt; text-align: justify"><font style="font-size: 10pt">Total property and equipment</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">22,212</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">10,592</font></td> <td style="padding-bottom: 2.5pt">&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><i>Financial Instruments and Fair Value Measurements</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">The fair value of a financial instrument represents the amount at which the instrument could be exchanged in a current transaction between willing parties, other than in a forced sale or liquidation. Fair value estimates are made at a specific point in time, based on relevant market information about the financial instrument. These estimates are subjective in nature and involve uncertainties and matters of judgment, and therefore cannot be determined with precision.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Accounting standards define fair value as the price that would be received from selling an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. Accounting standards establish a fair value hierarchy which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value and also establishes the following three levels of inputs that may be used to measure fair value:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Level 1 &#8212; quoted prices in active markets for identical assets or liabilities</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Level 2 &#8212; Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Level 3 &#8212; Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 35pt; background-color: white">The following methods and assumptions were used by the Company in estimating fair value disclosures for financial instruments:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 35pt; background-color: white">&#160;</p> <table cellspacing="0" cellpadding="0" style="width: 100%; background-color: white"> <tr style="vertical-align: top"> <td style="width: 1%; font: 12pt Times New Roman, Times, Serif"><font style="font-size: 10pt">&#9679;</font></td> <td style="width: 99%; font: 12pt Times New Roman, Times, Serif; text-align: justify"><font style="font-size: 10pt"><i>Cash and cash equivalents, restricted cash, operating lease related receivables, and accounts payable</i>: The amounts reported in the accompanying Consolidated Balance Sheets approximate fair value due to their short-term nature</font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&#160;</p> <table cellspacing="0" cellpadding="0" style="width: 100%; background-color: white"> <tr style="vertical-align: top"> <td style="width: 1%; font: 12pt Times New Roman, Times, Serif"><font style="font-size: 10pt">&#9679;</font></td> <td style="width: 99%; font: 12pt Times New Roman, Times, Serif; text-align: justify"><font style="font-size: 10pt"><i>Goodwill, other intangible assets, and long-lived assets held and used:&#160;</i>The assets are measured at fair value when there is an indicator of impairment and recorded at fair value only when impairment is recognized or for a business combination. The fair values less costs to sell of long-lived assets or disposal groups held for sale are assessed each reporting period they remain classified as held for sale. Subsequent changes in the held for sale long-lived asset&#8217;s or disposal group&#8217;s fair value less cost to sell (increase or decrease) are reported as an adjustment to its carrying amount, except that the adjusted carrying amount cannot exceed the carrying amount of the long-lived asset or disposal group at the time it was initially classified as held for sale. [need to add the Level of inputs used]</font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><i>Stock-based compensation</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">The Company recognizes compensation expense for stock-based compensation in accordance with ASC Topic 718. For employee stock-based awards, the fair value of the award is calculated on the date of grant using the Black-Scholes method for stock options and the quoted price of our common stock for common shares; the expense is recognized over the service period for awards expected to vest. For non-employee stock-based awards, the fair value of the award on the date of grant is calculated in the same manner as employee awards. However, the awards are revalued at the end of each reporting period and the pro rata compensation expense is adjusted accordingly until such time the nonemployee award is fully vested, at which time the total compensation recognized to date equals the fair value of the stock-based award as calculated on the measurement date, which is the date at which the award recipient&#8217;s performance is complete. The estimation of stock-based awards that will ultimately vest requires judgment, and to the extent actual results or updated estimates differ from original estimates, such amounts are recorded as a cumulative adjustment in the period estimates are revised.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><i>Earnings (Loss) Per Share</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Basic earnings (loss) per share is computed by dividing net income (loss) by the weighted average number of common shares outstanding for the period. Diluted earnings (loss) per share is computed by dividing net income (loss) by the weighted average number of shares outstanding, noted above.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><i>Recent Accounting Pronouncements</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b><i>Revenue Recognition</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of January 1, 2018, the Company adopted ASU 2014-09 and all subsequent ASUs that modified ASC 606. As part of the implementation process the Company performed an analysis to identify accounting policies that needed to change and additional disclosures that are required. The Company considered factors such as customer contracts with unique revenue recognition considerations, the nature and type of goods and services offered, the degree to which contracts include multiple performance obligations or variable consideration, and the pattern in which revenue is currently recognized, among other things. All of the Company&#8217;s revenue streams were evaluated, and similar performance obligations resulted under the new standard. In addition, the Company considered recognition under the new standard and concluded the timing of the Company&#8217;s revenue recognition will remain the same. The Company has also evaluated the changes in controls and processes that are necessary to implement the new standard, and no material changes were required.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">CCI&#8217;s revenue predominantly represents consulting services agreements, which included providing services to physicians for billing insurance companies. The amounts reported as revenue are net of amounts remitted.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">EZ&#8217;s revenue from the sale of products are recognized when the sale is consummated and title is transferred. The Company and customer enter into an agreement which outlines the place and date of sale, purchase price, payment terms, and the assignment of rights and warranties from the Company to the customer. Management has identified the promise in the sale contract to be the transfer of ownership of the asset. Management believes the asset holds standalone value to the customer as it is not dependent on any other services for functionality purposes and therefore is distinct within the context of the contract and as described in ASC 606-10. As such, management has identified the transfer of the asset as the performance obligation. The transaction price is set at a fixed dollar amount per fixed quantity (number of assets) and is explicitly stated in each contract. Sales revenue is based on a set price for a set number of assets, which is allocated to the performance obligation discussed above, in its entirety. The Company has determined the date of transfer to the customer to be the date the customer obtains control and title over the asset and the date which revenue is to be recognized and payment is due. As such, there is no impact to the timing and amounts of revenue recognized for equipment sales related to the implementation of ASC 606.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b><i>Accounting for Leases</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">In February 2016, the FASB issued an accounting standard update that amends the accounting guidance on leases. The intent of this ASU is to increase transparency and comparability among organizations recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements. Lessors will account for leases using an approach that is substantially equivalent to existing U.S. GAAP for sales-type leases, direct financing leases and operating leases. Unlike current guidance, however, a lease with collectability uncertainties may be classified as a sales-type lease. If collectability of lease payments, plus any amount necessary to satisfy a lessee residual value guarantee, is not probable, lease payments received will be recognized as a deposit liability and the underlying assets will not be derecognized until collectability of the remaining amounts becomes probable. The ASU is effective for interim and annual periods beginning after December 15, 2018, with early adoption permitted, and must be adopted using a modified retrospective approach for leases that exist or are entered into after the beginning of the earliest comparative period in the financial statements. The Company plans to adopt this guidance on January 1, 2019, that standard&#8217;s effective date, and is currently in the process of determining the impact that the updated accounting guidance will have on the consolidated financial statements and related disclosures.&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b><i>Classification of Certain Cash Receipts and Cash Payments</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">In August 2016, the FASB issued an accounting standard update that provides guidance on the following eight specific cash flow classification issues: (1) debt prepayment or debt extinguishment costs; (2) settlement of zero-coupon debt instruments or other debt instruments with coupon interest rates that are insignificant in relation to the effective interest rate of the borrowing; (3) contingent consideration payments made after a business combination; (4) proceeds from the settlement of insurance claims; (5) proceeds from the settlement of corporate-owned life insurance policies, including bank-owned life insurance policies; (6) distributions received from equity method investees; (7) beneficial interests in securitization transactions; and (8) separately identifiable cash flows and application of the predominance principle. Current GAAP does not include specific guidance on these eight cash flow classification issues. The amendments of this ASU are effective for reporting periods beginning after December 15, 2017, with early adoption permitted. We will adopt this accounting standard update effective January 1, 2018. The provisions of this update will not have a material impact on our consolidated statements of cash flows.<b><i>&#160;</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b><i>Tax Cuts and Jobs Act </i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">In February 2018, the FASB issued ASU 2018-02, &#8220;Income Statement &#8211; Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income&#8221; to address stakeholder concerns about the guidance in current U.S. GAAP that requires deferred tax liabilities and assets to be adjusted for the effect of a change in tax laws or rates with the effect included in income from continuing operations in the reporting period that includes the enactment date. The amendments in this Update allow a reclassification from accumulated other comprehensive income to retained earnings for stranded tax effects resulting from the Tax Cuts and Jobs Act. The Company is currently evaluating the timing, methods and impact of adopting this new standard on the consolidated financial statements.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">Depreciation is provided using the straight-line method over the estimated useful lives of the assets, which are as follows:&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: justify">&#160;</td> <td style="padding-bottom: 1pt">&#160;</td> <td nowrap="nowrap" colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt">March 31, 2018</font></td> <td style="padding-bottom: 1pt">&#160;</td> <td style="padding-bottom: 1pt">&#160;</td> <td nowrap="nowrap" colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt">December 31, 2017</font></td> <td style="padding-bottom: 1pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 74%; text-align: justify"><font style="font-size: 10pt">Machinery and equipment &#8211; 7 years</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 10%; text-align: right"><font style="font-size: 10pt">31,801</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 10%; text-align: right"><font style="font-size: 10pt">19,195</font></td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1pt; text-align: justify"><font style="font-size: 10pt">Accumulated depreciation</font></td> <td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: black 1pt solid">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">(9,589</font></td> <td style="padding-bottom: 1pt"><font style="font-size: 10pt">)</font></td> <td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: black 1pt solid">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">(8,603</font></td> <td style="padding-bottom: 1pt"><font style="font-size: 10pt">)</font></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt; text-align: justify"><font style="font-size: 10pt">Total property and equipment</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">22,212</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">10,592</font></td> <td style="padding-bottom: 2.5pt">&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table presents the consideration of net assets purchased:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 81%; text-align: justify"><font style="font-size: 10pt">Cash</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 16%; text-align: right"><font style="font-size: 10pt">3,600,000</font></td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">1,751,580 shares of common stock issued</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">175,158</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify"><font style="font-size: 10pt">Note payable</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">2,500,000</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1pt; text-align: justify"><font style="font-size: 10pt">Imputed interest</font></td> <td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: black 1pt solid">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">(763,558</font></td> <td style="padding-bottom: 1pt"><font style="font-size: 10pt">)</font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table summarizes the fair values assigned to the assets acquired and liabilities assumed.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 81%; padding-left: 5.4pt; text-align: justify"><font style="font-size: 10pt">Cash</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 16%; text-align: right"><font style="font-size: 10pt">81,359</font></td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 5.4pt; text-align: justify"><font style="font-size: 10pt">Current assets</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">759,710</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 5.4pt; text-align: justify"><font style="font-size: 10pt">Other non-current assets</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">11,167</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 5.4pt; text-align: justify"><font style="font-size: 10pt">Intangible assets</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">4,313,000</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 5.4pt; text-align: justify"><font style="font-size: 10pt">Goodwill</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">3,313,226</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 5.4pt; text-align: justify"><font style="font-size: 10pt">Current liabilities</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">(1,343,880</font></td> <td><font style="font-size: 10pt">)</font></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1pt; padding-left: 5.4pt; text-align: justify"><font style="font-size: 10pt">Deferred tax liability</font></td> <td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: black 1pt solid">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">(1,622,982</font></td> <td style="padding-bottom: 1pt"><font style="font-size: 10pt">)</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt; padding-left: 5.4pt; text-align: justify"><font style="font-size: 10pt">Net assets acquired</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">5,511,600</font></td> <td style="padding-bottom: 2.5pt">&#160;</td></tr> </table> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: center"><font style="font-size: 10pt">(Unaudited) </font><br /> <font style="font-size: 10pt">Pro Forma Results </font><br /> <font style="font-size: 10pt">Three months ended March 31,</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: center"><font style="font-size: 10pt">2017</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: center">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 87%; padding-bottom: 2.5pt"><font style="font-size: 10pt">Revenues</font></td> <td style="width: 1%; padding-bottom: 2.5pt">&#160;</td> <td style="width: 1%; border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="width: 10%; border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">1,232,278</font></td> <td style="width: 1%; padding-bottom: 2.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">Income before income taxes</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">82,224</font></td> <td style="padding-bottom: 2.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">Basic and fully diluted earnings (loss) per share</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">0.00</font></td> <td style="padding-bottom: 2.5pt">&#160;</td></tr> </table> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center"><font style="font-size: 10pt"><b>Amortizing</b></font></td> <td>&#160;</td> <td style="text-align: center"><font style="font-size: 10pt"><b>Estimates</b></font></td> <td>&#160;</td> <td colspan="2" style="text-align: center"><font style="font-size: 10pt"><b>Gross</b></font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt"><b>Intangible Assets</b></font></td> <td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt"><b>Useful Life</b></font></td> <td style="padding-bottom: 1pt">&#160;</td> <td nowrap="nowrap" colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt"><b>Carrying Amount</b></font></td> <td style="padding-bottom: 1pt">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">&#160;</td> <td>&#160;</td> <td style="text-align: justify">&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: justify">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 74%; text-align: justify"><font style="font-size: 10pt">Customer Lists</font></td> <td style="width: 1%">&#160;</td> <td style="width: 12%; padding-left: 5.4pt; text-align: justify"><font style="font-size: 10pt">10 years</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 10%; text-align: right"><font style="font-size: 10pt">2,653,000</font></td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify"><font style="font-size: 10pt">Tradenames</font></td> <td>&#160;</td> <td style="padding-left: 5.4pt; text-align: justify"><font style="font-size: 10pt">15 years</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">377,000</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify"><font style="font-size: 10pt">IP Technologies</font></td> <td>&#160;</td> <td style="padding-left: 5.4pt; text-align: justify"><font style="font-size: 10pt">10 years</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">819,000</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1pt; text-align: justify"><font style="font-size: 10pt">Non-compete</font></td> <td style="padding-bottom: 1pt">&#160;</td> <td style="padding-bottom: 1pt; padding-left: 5.4pt; text-align: justify"><font style="font-size: 10pt">5 years</font></td> <td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: black 1pt solid">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">464,000</font></td> <td style="padding-bottom: 1pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify">&#160;</td> <td>&#160;</td> <td style="padding-left: 5.4pt; text-align: justify">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">4,313,000</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1pt; text-align: justify"><font style="font-size: 10pt">Less: Accumulated Amortization</font></td> <td style="padding-bottom: 1pt">&#160;</td> <td style="padding-bottom: 1pt; padding-left: 5.4pt; text-align: justify">&#160;</td> <td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: black 1pt solid">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">(232,566</font></td> <td style="padding-bottom: 1pt"><font style="font-size: 10pt">)</font></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify">&#160;</td> <td>&#160;</td> <td style="padding-left: 5.4pt; text-align: justify">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt; text-align: justify">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt; padding-left: 5.4pt; text-align: justify">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">4,080,434</font></td> <td style="padding-bottom: 2.5pt">&#160;</td></tr> </table> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: center"><font style="font-size: 10pt">March 31,</font></td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: center"><font style="font-size: 10pt">December 31,</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: right">&#160;</td> <td style="padding-bottom: 1pt">&#160;</td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt">2018</font></td> <td style="padding-bottom: 1pt">&#160;</td> <td style="padding-bottom: 1pt">&#160;</td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt">2017</font></td> <td style="padding-bottom: 1pt">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 74%"><font style="font-size: 10pt">Note payable &#8211; monthly interest, 12.75% per annum, matures on September 29, 2020</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 10%; text-align: right"><font style="font-size: 10pt">5,000,000</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 10%; text-align: right"><font style="font-size: 10pt">5,000,000</font></td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Less discounts</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">(411,121</font></td> <td><font style="font-size: 10pt">)</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">(452,233</font></td> <td><font style="font-size: 10pt">)</font></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Note payable &#8211; monthly interest, 12.75% per annum, matures on September 30, 2022</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">2,500,000</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">2,500,000</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1pt"><font style="font-size: 10pt">Less discounts</font></td> <td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: black 1pt solid">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">(646,157</font></td> <td style="padding-bottom: 1pt"><font style="font-size: 10pt">)</font></td> <td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: black 1pt solid">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">(704,858</font></td> <td style="padding-bottom: 1pt"><font style="font-size: 10pt">)</font></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Subtotal</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">6,442,722</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">6,342,909</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1pt"><font style="font-size: 10pt">Less: current portion, net of discount $399,252</font></td> <td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: black 1pt solid">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">265,196</font></td> <td style="padding-bottom: 1pt">&#160;</td> <td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: black 1pt solid">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">265,196</font></td> <td style="padding-bottom: 1pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">Long- term portion</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">6,177,526</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">6,077,713</font></td> <td style="padding-bottom: 2.5pt">&#160;</td></tr> </table> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Principal payments on the above notes mature as follows:</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: right"><font style="font-size: 10pt">Year ending December 31:</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: right"><font style="font-size: 10pt">2018</font></td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">265,196</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">265,196</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: right"><font style="font-size: 10pt">2019</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">301,057</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">301,057</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: right"><font style="font-size: 10pt">2020</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">5,341,766</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">5,341,766</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: right"><font style="font-size: 10pt">2021</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">387,980</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">387,980</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1pt; text-align: right"><font style="font-size: 10pt">2022</font></td> <td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: black 1pt solid">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">440,443</font></td> <td style="padding-bottom: 1pt">&#160;</td> <td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: black 1pt solid">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">440,443</font></td> <td style="padding-bottom: 1pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt; text-align: right"><font style="font-size: 10pt">Thereafter</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">6,736,442</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">6,736,442</font></td> <td style="padding-bottom: 2.5pt">&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><b>&#160;</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table present selected financial information about the Company&#8217;s reportable segments for the three months ended March 31, 2018.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>For&#160;the&#160;three months</b>&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>ended&#160;March 31,&#160;2018</b>&#160;</p></td> <td style="padding-bottom: 1pt">&#160;</td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt"><b>Consolidated</b></font></td> <td style="padding-bottom: 1pt">&#160;</td> <td style="padding-bottom: 1pt">&#160;</td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt"><b>Ancillary Program</b></font></td> <td style="padding-bottom: 1pt">&#160;</td> <td style="padding-bottom: 1pt">&#160;</td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt"><b>Prescription Medicine</b></font></td> <td style="padding-bottom: 1pt">&#160;</td> <td style="padding-bottom: 1pt">&#160;</td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt"><b>Corporate</b></font></td> <td style="padding-bottom: 1pt">&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 48%"><font style="font-size: 10pt">Revenues</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 10%; text-align: right"><font style="font-size: 10pt">1,924,832</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 10%; text-align: right"><font style="font-size: 10pt">1,444,060</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 10%; text-align: right"><font style="font-size: 10pt">480,772</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 10%; text-align: right"><font style="font-size: 10pt">&#8212;</font></td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Cost of Revenue</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">376,096</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">&#8212;</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">376,096</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">&#8212;</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Long-lived assets</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">7,415,872</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">6,395,764</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">1,020,108</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">&#8212;</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Income (loss) before income tax</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">188,996</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">671,897</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">95,523</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">(578,424</font></td> <td><font style="font-size: 10pt">)</font></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Identifiable assets</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">4,102,646</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">3,082,538</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">1,020,108</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">&#8212;</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Depreciation and amortization</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">120,179</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">986</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">&#8212;</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">119,193</font></td> <td>&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 1 &#8211; Summary of Significant Accounting Policies </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">The significant accounting policies of Health-Right Discoveries, Inc. and its subsidiaries (collectively, the &#8220;<b>Company</b>&#8221; or &#8220;<b>HRD</b>&#8221;) were described in Note 1 to the audited consolidated financial statements included in the Company&#8217;s 2017 Annual Report on Form 10-K (&#8220;<b>2017 Form 10-K</b>&#8221;). There have been no significant changes in the Company&#8217;s significant accounting policies for the three months ended March 31, 2018.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><i>Basis of Presentation</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in conformity with accounting principles generally accepted in the United States (&#8220;<b>GAAP</b>&#8221;) for interim financial information and in accordance with the rules and regulations of the Securities and Exchange Commission.&#160; Therefore, they do not include all information and footnotes normally included in annual consolidated financial statements and should be read in conjunction with the consolidated financial statement and notes thereto included in the 2017 Form 10-K for the year ended December 31, 2017. In the opinion of the Company&#8217;s management, the accompanying unaudited condensed consolidated financial statements contain all the adjustments necessary (consisting only of normal recurring accruals) to present the financial position of the Company as of March 31, 2018 and the results of operations and cash flows for the periods presented. The results of operations for the three months ended March 31, 2018 are not necessarily indicative of the operating results for the full fiscal year or any future period.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><i>Use of Estimates</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">The preparation of the financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements and the reported amounts of revenue and expenses during the reporting periods. Actual results could differ from those estimates. Certain of the Company&#8217;s estimates could be affected by external conditions, including those unique to its industry, and general economic conditions. It is possible that these external factors could have an effect on the Company&#8217;s estimates that could cause actual results to differ from its estimates. The Company re-evaluates all of its accounting estimates at least quarterly based on these conditions and record adjustments when necessary.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><i>Inventories</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Inventories, which consist of the Company&#8217;s product held for resale, are stated at the lower of cost, determined using the first-in, first-out, or net realizable value. Net realizable value is the estimated selling price, in the ordinary course of business, less estimated costs to complete and dispose of the product.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">If the Company identifies excess, obsolete or unsalable items, its inventories are written down to their realizable value in the period in which the impairment is first identified. Shipping and handling costs incurred for inventory purchases and product shipments are recorded in cost of sales in the Company&#8217;s statements of operations. In the first quarter of 2018 and 2017, the Company recorded a loss of $-0- due to management&#8217;s estimate of obsolete inventory.&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><i>Property and Equipment</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white; text-align: justify">Property and equipment are stated at cost. Expenditures for additions are capitalized, repairs and maintenance are expensed as incurred. Depreciation is provided using the straight-line method over the estimated useful lives of the assets, which are as follows:&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: justify">&#160;</td> <td style="padding-bottom: 1pt">&#160;</td> <td colspan="2" style="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt">March 31, 2018</font></td> <td style="padding-bottom: 1pt">&#160;</td> <td style="padding-bottom: 1pt">&#160;</td> <td colspan="2" style="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt">December 31, 2017</font></td> <td style="padding-bottom: 1pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 74%; text-align: justify"><font style="font-size: 10pt">Machinery and equipment &#8211; 7 years</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 10%; text-align: right"><font style="font-size: 10pt">31,801</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 10%; text-align: right"><font style="font-size: 10pt">19,195</font></td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1pt; text-align: justify"><font style="font-size: 10pt">Accumulated depreciation</font></td> <td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: black 1pt solid">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">(9,589</font></td> <td style="padding-bottom: 1pt"><font style="font-size: 10pt">)</font></td> <td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: black 1pt solid">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">(8,603</font></td> <td style="padding-bottom: 1pt"><font style="font-size: 10pt">)</font></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt; text-align: justify"><font style="font-size: 10pt">Total property and equipment</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">22,212</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">10,592</font></td> <td style="padding-bottom: 2.5pt">&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in; background-color: white">&#160;&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><i>Financial Instruments and Fair Value Measurements</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">The fair value of a financial instrument represents the amount at which the instrument could be exchanged in a current transaction between willing parties, other than in a forced sale or liquidation. Fair value estimates are made at a specific point in time, based on relevant market information about the financial instrument. These estimates are subjective in nature and involve uncertainties and matters of judgment, and therefore cannot be determined with precision.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Accounting standards define fair value as the price that would be received from selling an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. Accounting standards establish a fair value hierarchy which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value and also establishes the following three levels of inputs that may be used to measure fair value:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Level 1 &#8212; quoted prices in active markets for identical assets or liabilities</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Level 2 &#8212; Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Level 3 &#8212; Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 35pt; background-color: white">The following methods and assumptions were used by the Company in estimating fair value disclosures for financial instruments:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 35pt; background-color: white">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; background-color: white"> <tr style="vertical-align: top"> <td style="width: 1%"><font style="font-size: 10pt">&#9679;</font></td> <td style="width: 99%; text-align: justify"><font style="font-size: 10pt"><i>Cash and cash equivalents, restricted cash, operating lease related receivables, and accounts payable</i>: The amounts reported in the accompanying Consolidated Balance Sheets approximate fair value due to their short-term nature</font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; background-color: white"> <tr style="vertical-align: top"> <td style="width: 1%"><font style="font-size: 10pt">&#9679;</font></td> <td style="width: 99%; text-align: justify"><font style="font-size: 10pt"><i>Goodwill, other intangible assets, and long-lived assets held and used:&#160;</i>The assets are measured at fair value when there is an indicator of impairment and recorded at fair value only when impairment is recognized or for a business combination. The fair values less costs to sell of long-lived assets or disposal groups held for sale are assessed each reporting period they remain classified as held for sale. Subsequent changes in the held for sale long-lived asset&#8217;s or disposal group&#8217;s fair value less cost to sell (increase or decrease) are reported as an adjustment to its carrying amount, except that the adjusted carrying amount cannot exceed the carrying amount of the long-lived asset or disposal group at the time it was initially classified as held for sale. [need to add the Level of inputs used]</font></td></tr> </table> <p style="margin-top: 0; margin-bottom: 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><i>Stock-based compensation</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">The Company recognizes compensation expense for stock-based compensation in accordance with ASC Topic 718. For employee stock-based awards, the fair value of the award is calculated on the date of grant using the Black-Scholes method for stock options and the quoted price of our common stock for common shares; the expense is recognized over the service period for awards expected to vest. For non-employee stock-based awards, the fair value of the award on the date of grant is calculated in the same manner as employee awards. However, the awards are revalued at the end of each reporting period and the pro rata compensation expense is adjusted accordingly until such time the nonemployee award is fully vested, at which time the total compensation recognized to date equals the fair value of the stock-based award as calculated on the measurement date, which is the date at which the award recipient&#8217;s performance is complete. The estimation of stock-based awards that will ultimately vest requires judgment, and to the extent actual results or updated estimates differ from original estimates, such amounts are recorded as a cumulative adjustment in the period estimates are revised.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><i>Earnings (Loss) Per Share</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Basic earnings (loss) per share is computed by dividing net income (loss) by the weighted average number of common shares outstanding for the period. Diluted earnings (loss) per share is computed by dividing net income (loss) by the weighted average number of shares outstanding, noted above.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><i>Recent Accounting Pronouncements</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b><i>Revenue Recognition</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of January 1, 2018, the Company adopted ASU 2014-09 and all subsequent ASUs that modified ASC 606. As part of the implementation process the Company performed an analysis to identify accounting policies that needed to change and additional disclosures that are required. The Company considered factors such as customer contracts with unique revenue recognition considerations, the nature and type of goods and services offered, the degree to which contracts include multiple performance obligations or variable consideration, and the pattern in which revenue is currently recognized, among other things. All of the Company&#8217;s revenue streams were evaluated, and similar performance obligations resulted under the new standard. In addition, the Company considered recognition under the new standard and concluded the timing of the Company&#8217;s revenue recognition will remain the same. The Company has also evaluated the changes in controls and processes that are necessary to implement the new standard, and no material changes were required.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">CCI&#8217;s revenue predominantly represents consulting services agreements, which included providing services to physicians for billing insurance companies. The amounts reported as revenue are net of amounts remitted.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">EZ&#8217;s revenue from the sale of products are recognized when the sale is consummated and title is transferred. The Company and customer enter into an agreement which outlines the place and date of sale, purchase price, payment terms, and the assignment of rights and warranties from the Company to the customer. Management has identified the promise in the sale contract to be the transfer of ownership of the asset. Management believes the asset holds standalone value to the customer as it is not dependent on any other services for functionality purposes and therefore is distinct within the context of the contract and as described in ASC 606-10. As such, management has identified the transfer of the asset as the performance obligation. The transaction price is set at a fixed dollar amount per fixed quantity (number of assets) and is explicitly stated in each contract. Sales revenue is based on a set price for a set number of assets, which is allocated to the performance obligation discussed above, in its entirety. The Company has determined the date of transfer to the customer to be the date the customer obtains control and title over the asset and the date which revenue is to be recognized and payment is due. As such, there is no impact to the timing and amounts of revenue recognized for equipment sales related to the implementation of ASC 606.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b><i>Accounting for Leases</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">In February 2016, the FASB issued an accounting standard update that amends the accounting guidance on leases. The intent of this ASU is to increase transparency and comparability among organizations recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements. Lessors will account for leases using an approach that is substantially equivalent to existing U.S. GAAP for sales-type leases, direct financing leases and operating leases. Unlike current guidance, however, a lease with collectability uncertainties may be classified as a sales-type lease. If collectability of lease payments, plus any amount necessary to satisfy a lessee residual value guarantee, is not probable, lease payments received will be recognized as a deposit liability and the underlying assets will not be derecognized until collectability of the remaining amounts becomes probable. The ASU is effective for interim and annual periods beginning after December 15, 2018, with early adoption permitted, and must be adopted using a modified retrospective approach for leases that exist or are entered into after the beginning of the earliest comparative period in the financial statements. The Company plans to adopt this guidance on January 1, 2019, that standard&#8217;s effective date, and is currently in the process of determining the impact that the updated accounting guidance will have on the consolidated financial statements and related disclosures.&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b><i>Classification of Certain Cash Receipts and Cash Payments</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">In August 2016, the FASB issued an accounting standard update that provides guidance on the following eight specific cash flow classification issues: (1) debt prepayment or debt extinguishment costs; (2) settlement of zero-coupon debt instruments or other debt instruments with coupon interest rates that are insignificant in relation to the effective interest rate of the borrowing; (3) contingent consideration payments made after a business combination; (4) proceeds from the settlement of insurance claims; (5) proceeds from the settlement of corporate-owned life insurance policies, including bank-owned life insurance policies; (6) distributions received from equity method investees; (7) beneficial interests in securitization transactions; and (8) separately identifiable cash flows and application of the predominance principle. Current GAAP does not include specific guidance on these eight cash flow classification issues. The amendments of this ASU are effective for reporting periods beginning after December 15, 2017, with early adoption permitted. We will adopt this accounting standard update effective January 1, 2018. The provisions of this update will not have a material impact on our consolidated statements of cash flows.<b><i>&#160;</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b><i>Tax Cuts and Jobs Act </i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">In February 2018, the FASB issued ASU 2018-02, &#8220;Income Statement &#8211; Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income&#8221; to address stakeholder concerns about the guidance in current U.S. GAAP that requires deferred tax liabilities and assets to be adjusted for the effect of a change in tax laws or rates with the effect included in income from continuing operations in the reporting period that includes the enactment date. The amendments in this Update allow a reclassification from accumulated other comprehensive income to retained earnings for stranded tax effects resulting from the Tax Cuts and Jobs Act. The Company is currently evaluating the timing, methods and impact of adopting this new standard on the consolidated financial statements.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><b>NOTE 5 &#8211; Related Party</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Since inception, the Company has relied in large part on loans from James Pande and David Hopkins, its principal shareholders, to fund its operations.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Mr. Pande and Mr. Hopkins advanced money to help fund the Company&#8217;s operations. Interest rates ranged from 2.9% - 7.5%, per annum. The balance due as of March 31, 2018 and December 31, 2017 was $0, respectively. The related party loan balance of $33,512 as of December 31, 2017 represents reimbursed expenses owed to shareholder.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p> <p style="font: 10pt TimesNewRoman,serif; margin: 0; text-align: justify">As of March 31, 2018 and December 31, 2017, the Company has unpaid and accrued salary to its President in the amount of $157,000 and $182,000, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On January 10, 2018, the Company entered into employment agreement with David Hopkins, its President, effective as of January 1, 2018. Pursuant to the employment agreement, Mr. Hopkins assumed the additional position of Chief Executive Officer of the Company. The employment agreement is for an initial term of three (3) and automatically renews for additional three (3) year periods, provided that the Company achieves Adjusted EBITDA (as defined) of $3,500,000 for any calendar year during the initial term and any renewal term.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The employment agreement provides for an initial base salary of $175,000. In the event in any calendar year during the initial term or any renewal term, HRD achieves Adjusted EBITDA of $3,500,000, Mr. Hopkins&#8217; annual base salary shall automatically increase to $250,000 and in the event in any calendar year during the initial term or any renewal term, the Company achieves Adjusted EBITDA of $5,000,000, his annual base salary shall automatically increase to $325,000. Mr. Hopkins will also receive a $600 per month car allowance while the employment agreement is in effect.</p> <p style="font: 10pt Calibri, Helvetica, Sans-Serif; margin: 0; color: #1F497D">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In addition to the foregoing, pursuant to the employment agreement, Mr. Hopkins was granted an option to purchase 525,000 shares of HRD common stock under the Company&#8217;s 2015 Stock Incentive Plan at an exercise price of $0.35 per share. The option vests in six equal semi-annual installments commencing June 30, 2018, expires the ten (10) years from the date of grant and is otherwise subject to the terms of the Incentive Plan.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 7 &#8211; 2015 Incentive Stock Plan</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our 2015 Incentive Stock Plan (the &#8220;<b>Incentive Plan</b>&#8221;) provides for equity incentives to be granted to our employees, executive officers or directors or to key advisers or consultants. Equity incentives may be in the form of stock options with an exercise price not less than the fair market value of the underlying shares as determined pursuant to the Incentive Plan, restricted stock awards, other stock based awards, or any combination of the foregoing. The Incentive Plan is administered by the board of directors. 3,000,000 shares of our common stock are reserved for issuance pursuant to the exercise of awards under the Incentive Plan. The number of shares so reserved automatically adjusts upward on January 1 of each year, so that the number of shares covered by the Incentive Plan is equal to 15% of our issued and outstanding common stock. As of March 31, 2018, options to purchase 1,266,666 shares at an exercise price of $0.35 per share have been granted and are outstanding under the Incentive Plan.</p> 175000 325000 600 525000 P10Y EX-101.SCH 5 cik0001537663-20180331.xsd XBRL SCHEMA FILE 00000001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS(Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000006 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - Acquisition link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - Intangible Assets link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - Notes payable link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - Related Party link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - 2015 Incentive Stock Plan link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - Business Segment Information link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - Subsequent events link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - Acquisition (Tables) link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - Intangible Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - Notes payable (Tables) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - Business Segment Information (Table) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - Summary of Significant Accounting Policies (Details) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - Summary of Significant Accounting Policies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - Acquisition (Details) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - Acquisition (Details 1) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - Acquisition (Details 2) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - Acquisition (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - Intangible Assets (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - Notes payable (Details) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - Notes payable (Details 1) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - Notes payable (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - Related Party (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000034 - Disclosure - Stockholders' Equity (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000035 - Disclosure - 2015 Incentive Stock Plan (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000036 - Disclosure - Income Taxes (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000037 - Disclosure - Business Segment Information (Details) link:presentationLink link:calculationLink link:definitionLink 00000038 - Disclosure - Business Segment Information (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 6 cik0001537663-20180331_cal.xml XBRL CALCULATION FILE EX-101.DEF 7 cik0001537663-20180331_def.xml XBRL DEFINITION FILE EX-101.LAB 8 cik0001537663-20180331_lab.xml XBRL LABEL FILE Business Acquisition [Axis] Common Compounds Inc EzPharmaRx LLC Finite-Lived Intangible Assets by Major Class [Axis] Customer Lists [Member] Trade Names [Member] IP Technologies [Member] Noncompete [Member] Long-term Debt, Type [Axis] Notes Payable One [Member] Notes Payable Two [Member] Business Acquisition [Axis] Lender Seller Derivative Instrument [Axis] 2015 Stock Option Incentive Plan [Member] Related Party [Axis] Mr. James. Pande [Member] Secured Promissory [Member] Long-term Debt, Type [Axis] Minimum [Member] Maximum [Member] Mr. David Hopkins [Member] Shareholder [Member] Segments [Axis] Ancillary Program [Member] Prescription Medicine [Member] Corporate [Member] Document And Entity Information Entity Registrant Name Entity Central Index Key Document Type Document Period End Date Amendment Flag Current Fiscal Year End Date Entity a Well-known Seasoned Issuer Entity a Voluntary Filer Entity's Reporting Status Current Entity Filer Category Entity Public Float Entity Common Stock, Shares Outstanding Document Fiscal Period Focus Document Fiscal Year Focus Statement of Financial Position [Abstract] ASSETS CURRENT ASSETS: Cash Accounts receivable, net Inventories Total Current Assets Property and Equipment, net Intangible assets, net Goodwill TOTAL ASSETS LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIENCY) CURRENT LIABILITIES: Accounts payable and accrued expenses Loans payable - related parties Salaries payable - related party Current portion - notes payable, net of discounts of $399,252 March 31, 2018 and December 31, 2017, respectively Total Current Liabilities Long-term Liabilities: Notes payable, net of discounts of $658,026 and $757,829 March 31, 2018 and December 31, 2017, respectively Deferred tax liability Total long-term liabilities Total liabilities STOCKHOLDERS' EQUITY (DEFICIENCY) Preferred Stock, .001 par value, 5,000,000 shares authorized No shares issued and outstanding March 31, 2018 and December 31, 2017, respectively Common Stock, .001 par value, 100,000,000 shares authorized 22,869,191 shares issued and outstanding March 31, 2018 and December 31, 2017, respectively Additional Paid in Capital Accumulated Deficit Total stockholders' equity (deficiency) TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIENCY) Notes payable, discounts current Notes payable, discounts noncurrent Preferred Stock, par value (in dollars per share) Preferred Stock, authorized Preferred Stock, issued Preferred Stock, outstanding Common Stock, par value (in dollars per share) Common Stock, authorized Common Stock, issued Common Stock, outstanding Income Statement [Abstract] Revenue Cost of Revenue Gross Profit COSTS AND EXPENSES: General and administrative Interest expense - related parties Interest expenses - other Total Cost and expenses Income (loss) before income tax provision Income tax provision NET INCOME (LOSS) Income (loss) per common share (in dollars per share) Weighted average common shares outstanding - basic and diluted (in shares) Statement of Cash Flows [Abstract] OPERATING ACTIVITIES: Net income (loss) Adjustments to reconcile net loss to net cash (used in) provided by operating activities: Depreciation expense Amortization Non-cash interest Deferred income tax benefit Changes in operating assets and liabilities Accounts receivable Inventories Accounts payable and accrued expenses Accrued salary to related party Accrued interest NET CASH PROVIDED BY (USED IN) OPERATING ACTIVITIES INVESTING ACTIVITIES: Purchase of property and equipment NET CASH USED IN INVESTING ACTIVITIES FINANCING ACTIVITIES: Proceeds of loan from related parties Repayment of related party loan NET CASH (USED IN) PROVIDED BY FINANCING ACTIVITIES INCREASE (DECREASE) IN CASH CASH - BEGINNING OF PERIOD CASH - END OF PERIOD Supplemental disclosures of cash flow information: Cash paid for interest Cash paid for income taxes Accounting Policies [Abstract] Summary of Significant Accounting Policies Business Combinations [Abstract] Acquisition Goodwill and Intangible Assets Disclosure [Abstract] Intangible Assets Debt Disclosure [Abstract] Notes payable Related Party Transactions [Abstract] Related Party Stockholders' Equity Attributable to Parent [Abstract] Stockholders' Equity Notes to Financial Statements 2015 Incentive Stock Plan Income Tax Disclosure [Abstract] Income Taxes Segment Reporting [Abstract] Business Segment Information Subsequent Events [Abstract] Subsequent events Basis of Presentation Use of Estimates Inventories Property and Equipment Financial Instruments and Fair Value Measurements Stock-based compensation Earnings (Loss) Per Share Recent Accounting Pronouncements Property and Equipment Consideration of net assets purchased Schedule of allocation of purchase cost Acquisition, Pro Forma Information Intangible Assets Schedule of note payable Schedule of Principal payments on maturity Business Segment Information Machinery and equipment, estimated useful life Machinery and equipment Accumulated depreciation Total property and equipment Obsolete inventory Statement [Table] Statement [Line Items] Cash 1,751,580 shares of common stock issued Note payable Imputed interest Total Purchase Price Cash Current assets Other non-current assets Intangible assets Goodwill Current liabilities Deferred tax liability Net assets acquired Revenues Income before income taxes Basic and fully diluted earnings (loss) per share Acquisition costs Purchase price Common stock issued for acquisition Cash Non-interest-bearing note Payable Interest on non-interest-bearing Identifiable intangible assets acquired Blended tax rate Estimates useful life Intangible Assets, Gross Less: Accumulated Amortization Intangible Assets, Net Amortization expense related the intangible assets Note payable Less discounts Subtotal Less: current portion, net of discount $399,252 Long- term portion Year ending December 31 2018 Year ending December 31 2019 Year ending December 31 2020 Year ending December 31 2021 Year ending December 31 2022 Thereafter Title of Individual [Axis] Financing Cost Interest rate Maturity Date Common stock issued Price per Share Discount Loan costs Promissory note Annual payment Interest imputed rate Range [Axis] Borrowing bear interest rate Outstanding amount Related party loan Base Salary Car allowance per month Unpaid compensation expenses to officers Option granted Option exerciseable price Term Common stock, authorized Common stock, par value (in dollars per share) Stock issued Preferred stock, authorized Preferred stock, par value (in dollars per share) Value of share issued for services Stock issued for option plan Number of share issued for services Income tax expense Effective tax rates Federal and state net operating loss carryovers Operating Loss Carryforwards, Expiration Date Description of utilization of NOLs Change in tax rate Revenues Long-lived assets Income (loss) before income tax Identifiable assets Depreciation and amortization Number of reportable segment Accrued salary to related party. Car allowance per month of officers. Amount paid for common stock issued. Imputed interest. It represents as a unpaid compensation expenses to officers. Promissory note. Stock option incentive plan 2015. Assets, Current Assets Liabilities, Current Liabilities, Noncurrent Liabilities Stockholders' Equity Attributable to Parent Liabilities and Equity Gross Profit Operating Expenses Increase (Decrease) in Inventories Increase (Decrease) in Accounts Payable and Accrued Liabilities Net Cash Provided by (Used in) Operating Activities, Continuing Operations Payments to Acquire Property, Plant, and Equipment Net Cash Provided by (Used in) Investing Activities Repayments of Related Party Debt Net Cash Provided by (Used in) Financing Activities, Continuing Operations Cash and Cash Equivalents, Period Increase (Decrease) Inventory, Policy [Policy Text Block] Property, Plant and Equipment [Table Text Block] Schedule of Indefinite-Lived Intangible Assets [Table Text Block] Schedule of Segment Reporting Information, by Segment [Table Text Block] Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Cash [Default Label] Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities Business Combination, Consideration Transferred Finite-Lived Intangible Assets, Accumulated Amortization Notes Payable Debt Instrument, Unamortized Discount Long-term Debt, Maturities, Repayments of Principal in Rolling after Year Five EX-101.PRE 9 cik0001537663-20180331_pre.xml XBRL PRESENTATION FILE XML 10 R1.htm IDEA: XBRL DOCUMENT v3.8.0.1
Document and Entity Information - shares
 3 Months Ended
Mar. 31, 2018
Apr. 14, 2018
Document And Entity Information    
Entity Registrant Name Health-Right Discoveries, Inc.  
Entity Central Index Key 0001537663  
Document Type 10-Q  
Document Period End Date Mar. 31, 2018  
Amendment Flag false  
Current Fiscal Year End Date --12-31  
Entity a Well-known Seasoned Issuer No  
Entity a Voluntary Filer No  
Entity's Reporting Status Current Yes  
Entity Filer Category Smaller Reporting Company  
Entity Common Stock, Shares Outstanding   22,869,191
Document Fiscal Period Focus Q1  
Document Fiscal Year Focus 2018  
XML 11 R2.htm IDEA: XBRL DOCUMENT v3.8.0.1
CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($)
Mar. 31, 2018
Dec. 31, 2017
CURRENT ASSETS:    
Cash $ 1,783,986 $ 1,458,942
Accounts receivable, net 481,056 471,112
Inventories 30,219 32,580
Total Current Assets 2,295,261 1,962,634
Property and Equipment, net 22,212 10,592
Intangible assets, net 4,080,434 4,196,717
Goodwill 3,313,226 3,313,226
TOTAL ASSETS 9,711,133 9,483,169
CURRENT LIABILITIES:    
Accounts payable and accrued expenses 1,343,984 1,346,317
Loans payable - related parties 33,512
Salaries payable - related party 157,000 182,000
Current portion - notes payable, net of discounts of $399,252 March 31, 2018 and December 31, 2017, respectively 265,196 265,196
Total Current Liabilities 1,766,180 1,827,025
Long-term Liabilities:    
Notes payable, net of discounts of $658,026 and $757,829 March 31, 2018 and December 31, 2017, respectively 6,177,526 6,077,713
Deferred tax liability 1,031,241 980,212
Total long-term liabilities 7,208,767 7,057,925
Total liabilities 8,974,947 8,884,950
STOCKHOLDERS' EQUITY (DEFICIENCY)    
Preferred Stock, .001 par value, 5,000,000 shares authorized No shares issued and outstanding March 31, 2018 and December 31, 2017, respectively
Common Stock, .001 par value, 100,000,000 shares authorized 22,869,191 shares issued and outstanding March 31, 2018 and December 31, 2017, respectively 22,869 22,869
Additional Paid in Capital 1,117,967 1,117,967
Accumulated Deficit (404,650) (542,617)
Total stockholders' equity (deficiency) 736,186 598,219
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIENCY) $ 9,711,133 $ 9,483,169
XML 12 R3.htm IDEA: XBRL DOCUMENT v3.8.0.1
CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) - USD ($)
Mar. 31, 2018
Dec. 31, 2017
Statement of Financial Position [Abstract]    
Notes payable, discounts current $ 399,252 $ 399,252
Notes payable, discounts noncurrent $ 658,026 $ 757,829
Preferred Stock, par value (in dollars per share) $ 0.001 $ 0.001
Preferred Stock, authorized 5,000,000 5,000,000
Preferred Stock, issued 0 0
Preferred Stock, outstanding 0 0
Common Stock, par value (in dollars per share) $ 0.001 $ 0.001
Common Stock, authorized 100,000,000 100,000,000
Common Stock, issued 22,869,191 22,869,191
Common Stock, outstanding 22,869,191 22,869,191
XML 13 R4.htm IDEA: XBRL DOCUMENT v3.8.0.1
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($)
 3 Months Ended
Mar. 31, 2018
Mar. 31, 2017
Income Statement [Abstract]    
Revenue $ 1,924,832
Cost of Revenue 376,096
Gross Profit 1,548,736
COSTS AND EXPENSES:    
General and administrative 1,103,462 18,767
Interest expense - related parties 2,352
Interest expenses - other 256,278
Total Cost and expenses 1,359,740 21,119
Income (loss) before income tax provision 188,996 (21,119)
Income tax provision 51,029
NET INCOME (LOSS) $ 137,967 $ (21,119)
Income (loss) per common share (in dollars per share) $ 0.01 $ (0.00)
Weighted average common shares outstanding - basic and diluted (in shares) 22,869,191 17,533,332
XML 14 R5.htm IDEA: XBRL DOCUMENT v3.8.0.1
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS(Unaudited) - USD ($)
 3 Months Ended
Mar. 31, 2018
Mar. 31, 2017
OPERATING ACTIVITIES:    
Net income (loss) $ 137,967 $ (21,119)
Adjustments to reconcile net loss to net cash (used in) provided by operating activities:    
Depreciation expense 986
Amortization 116,283
Non-cash interest 99,813
Deferred income tax benefit 51,029
Changes in operating assets and liabilities    
Accounts receivable (9,944)
Inventories 2,361 (16,672)
Accounts payable and accrued expenses (2,332)
Accrued salary to related party (25,000) 13,000
Accrued interest 2,352
NET CASH PROVIDED BY (USED IN) OPERATING ACTIVITIES 371,163 (22,439)
INVESTING ACTIVITIES:    
Purchase of property and equipment (12,607)
NET CASH USED IN INVESTING ACTIVITIES (12,607)
FINANCING ACTIVITIES:    
Proceeds of loan from related parties 4,344
Repayment of related party loan (33,512)
NET CASH (USED IN) PROVIDED BY FINANCING ACTIVITIES (33,512) 4,344
INCREASE (DECREASE) IN CASH 325,044 (18,095)
CASH - BEGINNING OF PERIOD 1,458,942 18,373
CASH - END OF PERIOD 1,783,986 278
Supplemental disclosures of cash flow information:    
Cash paid for interest 159,374
Cash paid for income taxes
XML 15 R6.htm IDEA: XBRL DOCUMENT v3.8.0.1
Summary of Significant Accounting Policies
 3 Months Ended
Mar. 31, 2018
Accounting Policies [Abstract]  
Summary of Significant Accounting Policies

NOTE 1 – Summary of Significant Accounting Policies

 

The significant accounting policies of Health-Right Discoveries, Inc. and its subsidiaries (collectively, the “Company” or “HRD”) were described in Note 1 to the audited consolidated financial statements included in the Company’s 2017 Annual Report on Form 10-K (“2017 Form 10-K”). There have been no significant changes in the Company’s significant accounting policies for the three months ended March 31, 2018.

 

Basis of Presentation

 

The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in conformity with accounting principles generally accepted in the United States (“GAAP”) for interim financial information and in accordance with the rules and regulations of the Securities and Exchange Commission.  Therefore, they do not include all information and footnotes normally included in annual consolidated financial statements and should be read in conjunction with the consolidated financial statement and notes thereto included in the 2017 Form 10-K for the year ended December 31, 2017. In the opinion of the Company’s management, the accompanying unaudited condensed consolidated financial statements contain all the adjustments necessary (consisting only of normal recurring accruals) to present the financial position of the Company as of March 31, 2018 and the results of operations and cash flows for the periods presented. The results of operations for the three months ended March 31, 2018 are not necessarily indicative of the operating results for the full fiscal year or any future period.

 

Use of Estimates

 

The preparation of the financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements and the reported amounts of revenue and expenses during the reporting periods. Actual results could differ from those estimates. Certain of the Company’s estimates could be affected by external conditions, including those unique to its industry, and general economic conditions. It is possible that these external factors could have an effect on the Company’s estimates that could cause actual results to differ from its estimates. The Company re-evaluates all of its accounting estimates at least quarterly based on these conditions and record adjustments when necessary.

 

Inventories

 

Inventories, which consist of the Company’s product held for resale, are stated at the lower of cost, determined using the first-in, first-out, or net realizable value. Net realizable value is the estimated selling price, in the ordinary course of business, less estimated costs to complete and dispose of the product.

 

If the Company identifies excess, obsolete or unsalable items, its inventories are written down to their realizable value in the period in which the impairment is first identified. Shipping and handling costs incurred for inventory purchases and product shipments are recorded in cost of sales in the Company’s statements of operations. In the first quarter of 2018 and 2017, the Company recorded a loss of $-0- due to management’s estimate of obsolete inventory. 

 

Property and Equipment

 

Property and equipment are stated at cost. Expenditures for additions are capitalized, repairs and maintenance are expensed as incurred. Depreciation is provided using the straight-line method over the estimated useful lives of the assets, which are as follows: 

 

    March 31, 2018     December 31, 2017  
Machinery and equipment – 7 years   $ 31,801     $ 19,195  
Accumulated depreciation     (9,589 )     (8,603 )
Total property and equipment   $ 22,212     $ 10,592  

  

Financial Instruments and Fair Value Measurements

 

The fair value of a financial instrument represents the amount at which the instrument could be exchanged in a current transaction between willing parties, other than in a forced sale or liquidation. Fair value estimates are made at a specific point in time, based on relevant market information about the financial instrument. These estimates are subjective in nature and involve uncertainties and matters of judgment, and therefore cannot be determined with precision.

 

Accounting standards define fair value as the price that would be received from selling an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. Accounting standards establish a fair value hierarchy which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value and also establishes the following three levels of inputs that may be used to measure fair value:

 

Level 1 — quoted prices in active markets for identical assets or liabilities

 

Level 2 — Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities

 

Level 3 — Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities

 

The following methods and assumptions were used by the Company in estimating fair value disclosures for financial instruments:

 

● Cash and cash equivalents, restricted cash, operating lease related receivables, and accounts payable: The amounts reported in the accompanying Consolidated Balance Sheets approximate fair value due to their short-term nature

 

● Goodwill, other intangible assets, and long-lived assets held and used: The assets are measured at fair value when there is an indicator of impairment and recorded at fair value only when impairment is recognized or for a business combination. The fair values less costs to sell of long-lived assets or disposal groups held for sale are assessed each reporting period they remain classified as held for sale. Subsequent changes in the held for sale long-lived asset’s or disposal group’s fair value less cost to sell (increase or decrease) are reported as an adjustment to its carrying amount, except that the adjusted carrying amount cannot exceed the carrying amount of the long-lived asset or disposal group at the time it was initially classified as held for sale. [need to add the Level of inputs used]

 

Stock-based compensation

 

The Company recognizes compensation expense for stock-based compensation in accordance with ASC Topic 718. For employee stock-based awards, the fair value of the award is calculated on the date of grant using the Black-Scholes method for stock options and the quoted price of our common stock for common shares; the expense is recognized over the service period for awards expected to vest. For non-employee stock-based awards, the fair value of the award on the date of grant is calculated in the same manner as employee awards. However, the awards are revalued at the end of each reporting period and the pro rata compensation expense is adjusted accordingly until such time the nonemployee award is fully vested, at which time the total compensation recognized to date equals the fair value of the stock-based award as calculated on the measurement date, which is the date at which the award recipient’s performance is complete. The estimation of stock-based awards that will ultimately vest requires judgment, and to the extent actual results or updated estimates differ from original estimates, such amounts are recorded as a cumulative adjustment in the period estimates are revised.

 

Earnings (Loss) Per Share

 

Basic earnings (loss) per share is computed by dividing net income (loss) by the weighted average number of common shares outstanding for the period. Diluted earnings (loss) per share is computed by dividing net income (loss) by the weighted average number of shares outstanding, noted above.

 

Recent Accounting Pronouncements

 

Revenue Recognition

 

As of January 1, 2018, the Company adopted ASU 2014-09 and all subsequent ASUs that modified ASC 606. As part of the implementation process the Company performed an analysis to identify accounting policies that needed to change and additional disclosures that are required. The Company considered factors such as customer contracts with unique revenue recognition considerations, the nature and type of goods and services offered, the degree to which contracts include multiple performance obligations or variable consideration, and the pattern in which revenue is currently recognized, among other things. All of the Company’s revenue streams were evaluated, and similar performance obligations resulted under the new standard. In addition, the Company considered recognition under the new standard and concluded the timing of the Company’s revenue recognition will remain the same. The Company has also evaluated the changes in controls and processes that are necessary to implement the new standard, and no material changes were required.

 

CCI’s revenue predominantly represents consulting services agreements, which included providing services to physicians for billing insurance companies. The amounts reported as revenue are net of amounts remitted.

 

EZ’s revenue from the sale of products are recognized when the sale is consummated and title is transferred. The Company and customer enter into an agreement which outlines the place and date of sale, purchase price, payment terms, and the assignment of rights and warranties from the Company to the customer. Management has identified the promise in the sale contract to be the transfer of ownership of the asset. Management believes the asset holds standalone value to the customer as it is not dependent on any other services for functionality purposes and therefore is distinct within the context of the contract and as described in ASC 606-10. As such, management has identified the transfer of the asset as the performance obligation. The transaction price is set at a fixed dollar amount per fixed quantity (number of assets) and is explicitly stated in each contract. Sales revenue is based on a set price for a set number of assets, which is allocated to the performance obligation discussed above, in its entirety. The Company has determined the date of transfer to the customer to be the date the customer obtains control and title over the asset and the date which revenue is to be recognized and payment is due. As such, there is no impact to the timing and amounts of revenue recognized for equipment sales related to the implementation of ASC 606.

 

Accounting for Leases

 

In February 2016, the FASB issued an accounting standard update that amends the accounting guidance on leases. The intent of this ASU is to increase transparency and comparability among organizations recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements. Lessors will account for leases using an approach that is substantially equivalent to existing U.S. GAAP for sales-type leases, direct financing leases and operating leases. Unlike current guidance, however, a lease with collectability uncertainties may be classified as a sales-type lease. If collectability of lease payments, plus any amount necessary to satisfy a lessee residual value guarantee, is not probable, lease payments received will be recognized as a deposit liability and the underlying assets will not be derecognized until collectability of the remaining amounts becomes probable. The ASU is effective for interim and annual periods beginning after December 15, 2018, with early adoption permitted, and must be adopted using a modified retrospective approach for leases that exist or are entered into after the beginning of the earliest comparative period in the financial statements. The Company plans to adopt this guidance on January 1, 2019, that standard’s effective date, and is currently in the process of determining the impact that the updated accounting guidance will have on the consolidated financial statements and related disclosures. 

 

Classification of Certain Cash Receipts and Cash Payments

 

In August 2016, the FASB issued an accounting standard update that provides guidance on the following eight specific cash flow classification issues: (1) debt prepayment or debt extinguishment costs; (2) settlement of zero-coupon debt instruments or other debt instruments with coupon interest rates that are insignificant in relation to the effective interest rate of the borrowing; (3) contingent consideration payments made after a business combination; (4) proceeds from the settlement of insurance claims; (5) proceeds from the settlement of corporate-owned life insurance policies, including bank-owned life insurance policies; (6) distributions received from equity method investees; (7) beneficial interests in securitization transactions; and (8) separately identifiable cash flows and application of the predominance principle. Current GAAP does not include specific guidance on these eight cash flow classification issues. The amendments of this ASU are effective for reporting periods beginning after December 15, 2017, with early adoption permitted. We will adopt this accounting standard update effective January 1, 2018. The provisions of this update will not have a material impact on our consolidated statements of cash flows. 

 

Tax Cuts and Jobs Act

 

In February 2018, the FASB issued ASU 2018-02, “Income Statement – Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income” to address stakeholder concerns about the guidance in current U.S. GAAP that requires deferred tax liabilities and assets to be adjusted for the effect of a change in tax laws or rates with the effect included in income from continuing operations in the reporting period that includes the enactment date. The amendments in this Update allow a reclassification from accumulated other comprehensive income to retained earnings for stranded tax effects resulting from the Tax Cuts and Jobs Act. The Company is currently evaluating the timing, methods and impact of adopting this new standard on the consolidated financial statements.

 
XML 16 R7.htm IDEA: XBRL DOCUMENT v3.8.0.1
Acquisition
 3 Months Ended
Mar. 31, 2018
Business Combinations [Abstract]  
Acquisition

NOTE 2 – Acquisitions

 

The Company modified its business plan from building a platform of products in the nutraceutical and dietary supplement space to seeking acquisitions in the healthcare field. HRD identified two target companies for sale that fit their plan going forward of acquiring small, profitable, privately held companies in the healthcare space that generate at least $5 million in revenue and $1 million in EBITDA.

 

On September 29, 2017, the Company finalized a securities purchase agreement with CCI and EZRX to purchase 100% of their outstanding interests for $6.1 million plus 1,751,580 shares of its common stock.

 

In accordance with the acquisition method of accounting, the Company allocated the consideration to the net tangible and identifiable intangible assets based on their estimated fair values which were determined by an independent valuation performed by a third party.

 

Goodwill represents the excess of the purchase price over the fair value of the underlying net tangible and identifiable intangible assets.

 

The following table presents the consideration of net assets purchased:

 

Cash   $ 3,600,000  
1,751,580 shares of common stock issued     175,158  
Note payable     2,500,000  
Imputed interest     (763,558 )
Total Purchase Price   $ 5,511,600  

 

The assets acquired and liabilities assumed as part of our acquisition were recognized at their fair values as of the effective acquisition date, September 29, 2017, based upon an appraisal from a third party. The following table summarizes the fair values assigned to the assets acquired and liabilities assumed.

 

Cash   $ 81,359  
Current assets     759,710  
Other non-current assets     11,167  
Intangible assets     4,313,000  
Goodwill     3,313,226  
Current liabilities     (1,343,880 )
Deferred tax liability     (1,622,982 )
Net assets acquired   $ 5,511,600  

 

Acquisition costs of $410,000 were incurred and expensed for the year December 31, 2017. As part of the acquisition the company recognized deferred tax liabilities of $1,622,982 related to the unamortized identifiable intangible assets acquired in the amount of $4,313,000 using a blended 37.63% tax rate.

 

The following table provides unaudited pro forma results of operations for the three months ended March 31, 2017 as if the acquisitions had been consummated as of the beginning of that period presented. The pro forma results include the effect of certain purchase accounting adjustments, such as the estimated changes in depreciation and amortization expense on the acquired intangible assets. However, pro forma results do not include any anticipated cost savings or other effects of the planned integration of the companies. Accordingly, such amounts are not necessarily indicative of the results if the acquisition has occurred on the dates indicated, or which may occur in the future.

 

    (Unaudited)
Pro Forma Results
Three months ended March 31,		  
    2017  
       
Revenues   $ 1,232,278  
Income before income taxes   $ 82,224  
         
Basic and fully diluted earnings (loss) per share   $ 0.00  
XML 17 R8.htm IDEA: XBRL DOCUMENT v3.8.0.1
Intangible Assets
 3 Months Ended
Mar. 31, 2018
Goodwill and Intangible Assets Disclosure [Abstract]  
Intangible Assets

NOTE 3 – Intangible Assets  

 

Amortizing   Estimates   Gross  
Intangible Assets   Useful Life   Carrying Amount  
           
Customer Lists   10 years   $ 2,653,000  
Tradenames   15 years     377,000  
IP Technologies   10 years     819,000  
Non-compete   5 years     464,000  
          4,313,000  
Less: Accumulated Amortization         (232,566 )
             
        $ 4,080,434  

 

The amortization expense related to the intangible assets was $116,283 and $0 as of March 31, 2018 and 2017, respectively.

 

The valuation of the assets acquired and liabilities assumed in connection with this acquisition was based on fair values at the acquisition date. The assets purchased and liabilities assumed for these acquisitions have been reflected in the accompanying consolidated balance sheets.
XML 18 R9.htm IDEA: XBRL DOCUMENT v3.8.0.1
Notes payable
 3 Months Ended
Mar. 31, 2018
Debt Disclosure [Abstract]  
Notes payable

NOTE 4 – Notes payable

 

The Company obtained a secured convertible note with a lender for $5 million, interest is payable monthly, at 12.75% per annum, the note matures on September 29, 2020. The note can be converted at any time in whole or in part at $0.44 per share. In addition, the lender received 3,584,279 shares of common stock valued at $0.10 per share along with a 2% original issue discount. The total amount of the discount is $493,345. The Company had incurred $34,917 in loan costs. Both the discount and loan costs are presented as a reduction of the note payable.

 

The Company, as part of consideration for the purchase of CCI and EZRX, obtained a $2.5 million note payable. The note is non-interest bearing with 5 annual payments of $500,000, matures on September 30, 2022. Interest has been imputed at 12.75% per annum. Upon each annual payment date the holder may elect to convert the annual installment of the principal amount due into shares of common stock at $2 per share.

 

    March 31,     December 31,  
    2018     2017  
             
Note payable – monthly interest, 12.75% per annum, matures on September 29, 2020   $ 5,000,000     $ 5,000,000  
Less discounts     (411,121 )     (452,233 )
Note payable – monthly interest, 12.75% per annum, matures on September 30, 2022     2,500,000       2,500,000  
Less discounts     (646,157 )     (704,858 )
Subtotal     6,442,722       6,342,909  
Less: current portion, net of discount $399,252     265,196       265,196  
Long- term portion   $ 6,177,526     $ 6,077,713  
                 
Principal payments on the above notes mature as follows:                
Year ending December 31:                
2018   $ 265,196     $ 265,196  
2019     301,057       301,057  
2020     5,341,766       5,341,766  
2021     387,980       387,980  
2022     440,443       440,443  
Thereafter   $ 6,736,442     $ 6,736,442  
XML 19 R10.htm IDEA: XBRL DOCUMENT v3.8.0.1
Related Party
 3 Months Ended
Mar. 31, 2018
Related Party Transactions [Abstract]  
Related Party

NOTE 5 – Related Party

 

Since inception, the Company has relied in large part on loans from James Pande and David Hopkins, its principal shareholders, to fund its operations.

 

Mr. Pande and Mr. Hopkins advanced money to help fund the Company’s operations. Interest rates ranged from 2.9% - 7.5%, per annum. The balance due as of March 31, 2018 and December 31, 2017 was $0, respectively. The related party loan balance of $33,512 as of December 31, 2017 represents reimbursed expenses owed to shareholder.

 

As of March 31, 2018 and December 31, 2017, the Company has unpaid and accrued salary to its President in the amount of $157,000 and $182,000, respectively.

 

On January 10, 2018, the Company entered into employment agreement with David Hopkins, its President, effective as of January 1, 2018. Pursuant to the employment agreement, Mr. Hopkins assumed the additional position of Chief Executive Officer of the Company. The employment agreement is for an initial term of three (3) and automatically renews for additional three (3) year periods, provided that the Company achieves Adjusted EBITDA (as defined) of $3,500,000 for any calendar year during the initial term and any renewal term.

 

The employment agreement provides for an initial base salary of $175,000. In the event in any calendar year during the initial term or any renewal term, HRD achieves Adjusted EBITDA of $3,500,000, Mr. Hopkins’ annual base salary shall automatically increase to $250,000 and in the event in any calendar year during the initial term or any renewal term, the Company achieves Adjusted EBITDA of $5,000,000, his annual base salary shall automatically increase to $325,000. Mr. Hopkins will also receive a $600 per month car allowance while the employment agreement is in effect.

 

In addition to the foregoing, pursuant to the employment agreement, Mr. Hopkins was granted an option to purchase 525,000 shares of HRD common stock under the Company’s 2015 Stock Incentive Plan at an exercise price of $0.35 per share. The option vests in six equal semi-annual installments commencing June 30, 2018, expires the ten (10) years from the date of grant and is otherwise subject to the terms of the Incentive Plan.
XML 20 R11.htm IDEA: XBRL DOCUMENT v3.8.0.1
Stockholders' Equity
 3 Months Ended
Mar. 31, 2018
STOCKHOLDERS' EQUITY (DEFICIENCY)  
Stockholders' Equity

NOTE 6 – Stockholders’ Equity

 

The Company has authorized 100,000,000 shares of common stock $.001 par value and 5,000,000 shares of preferred stock $.001 par value.

 

On September 29, 2017, the Company issued 1,751,580 shares of common stock for the purchase of CCI and EZRX (see Note 2). Also, on September 29, 2017, the Company issued 3,584,279 shares of its common stock in connection with its $5 million note (see Note 4).
XML 21 R12.htm IDEA: XBRL DOCUMENT v3.8.0.1
2015 Incentive Stock Plan
 3 Months Ended
Mar. 31, 2018
Notes to Financial Statements  
2015 Incentive Stock Plan

NOTE 7 – 2015 Incentive Stock Plan

 

Our 2015 Incentive Stock Plan (the “Incentive Plan”) provides for equity incentives to be granted to our employees, executive officers or directors or to key advisers or consultants. Equity incentives may be in the form of stock options with an exercise price not less than the fair market value of the underlying shares as determined pursuant to the Incentive Plan, restricted stock awards, other stock based awards, or any combination of the foregoing. The Incentive Plan is administered by the board of directors. 3,000,000 shares of our common stock are reserved for issuance pursuant to the exercise of awards under the Incentive Plan. The number of shares so reserved automatically adjusts upward on January 1 of each year, so that the number of shares covered by the Incentive Plan is equal to 15% of our issued and outstanding common stock. As of March 31, 2018, options to purchase 1,266,666 shares at an exercise price of $0.35 per share have been granted and are outstanding under the Incentive Plan.
XML 22 R13.htm IDEA: XBRL DOCUMENT v3.8.0.1
Income Taxes
 3 Months Ended
Mar. 31, 2018
Income Tax Disclosure [Abstract]  
Income Taxes

NOTE 8 – Income Taxes

 

Income tax expense for the three months ended March 31, 2018 and 2017 was $51,029 and $-0-, respectively. The effective tax rates for the three months ended March 31, 2018 and 2017 were 27% and 38.5%, respectively. The 2018 tax rate reflects the enactment of the Tax Cuts and Jobs Act of 2017 (the “Act”) which made significant changes to the Internal Revenue Code. Changes include, but are not limited to, a corporate tax rate decrease from 35% to 21% effective for tax years beginning after December 31, 2017.

 

As of December 31, 2017, the Company had approximately $566,304 of federal and state net operating loss carryovers (“NOLs”) which begin to expire in 2031.  Utilization of the NOLs may be subject to limitation under the Internal Revenue Code Section 382 should there be a greater than 50% ownership change as determined under regulations.  

 

In assessing the realization of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will be realized.  The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible.  Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies in making this assessment.  Based on the assessment, management has established a full valuation allowance against the entire deferred tax asset relating to NOLs for every period because it is more likely than not that all of the deferred tax asset will not be realized.

 

The Company files U.S. federal and state of Florida and Arkansas tax returns that are subject to audit by tax authorities beginning with the year ended December 31, 2013. The Company’s policy is to classify assessments, if any, for tax and related interest and penalties as tax expense.
XML 23 R14.htm IDEA: XBRL DOCUMENT v3.8.0.1
Business Segment Information
 3 Months Ended
Mar. 31, 2018
Segment Reporting [Abstract]  
Business Segment Information

NOTE 9 – Business Segment Information

 

The Company has two reportable segments (ancillary program and prescription medicine) supported by a corporate group which conducts activities that are non-segment specific. The following table present selected financial information about the Company’s reportable segments for the three months ended March 31, 2018.

 

For the three months 

ended March 31, 2018 

   Consolidated     Ancillary Program     Prescription Medicine     Corporate  
                         
Revenues   $ 1,924,832     $ 1,444,060     $ 480,772     $ —  
Cost of Revenue     376,096       —       376,096       —  
Long-lived assets     7,415,872       6,395,764       1,020,108       —  
Income (loss) before income tax     188,996       671,897       95,523       (578,424 )
Identifiable assets     4,102,646       3,082,538       1,020,108       —  
Depreciation and amortization     120,179       986       —       119,193  

 

The Company only had one reportable segment for the three months ended March 31, 2017.
XML 24 R15.htm IDEA: XBRL DOCUMENT v3.8.0.1
Subsequent events
 3 Months Ended
Mar. 31, 2018
Subsequent Events [Abstract]  
Subsequent events

NOTE 10 – Subsequent Events

 

The Company has evaluated subsequent events through the date that the financial statements were issued and determined that there were no subsequent events requiring adjustment to or disclosure in the financial statements.
XML 25 R16.htm IDEA: XBRL DOCUMENT v3.8.0.1
Summary of Significant Accounting Policies (Policies)
 3 Months Ended
Mar. 31, 2018
Accounting Policies [Abstract]  
Basis of Presentation

Basis of Presentation

 

The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in conformity with accounting principles generally accepted in the United States (“GAAP”) for interim financial information and in accordance with the rules and regulations of the Securities and Exchange Commission.  Therefore, they do not include all information and footnotes normally included in annual consolidated financial statements and should be read in conjunction with the consolidated financial statement and notes thereto included in the 2017 Form 10-K for the year ended December 31, 2017. In the opinion of the Company’s management, the accompanying unaudited condensed consolidated financial statements contain all the adjustments necessary (consisting only of normal recurring accruals) to present the financial position of the Company as of March 31, 2018 and the results of operations and cash flows for the periods presented. The results of operations for the three months ended March 31, 2018 are not necessarily indicative of the operating results for the full fiscal year or any future period.
Use of Estimates

Use of Estimates

 

The preparation of the financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements and the reported amounts of revenue and expenses during the reporting periods. Actual results could differ from those estimates. Certain of the Company’s estimates could be affected by external conditions, including those unique to its industry, and general economic conditions. It is possible that these external factors could have an effect on the Company’s estimates that could cause actual results to differ from its estimates. The Company re-evaluates all of its accounting estimates at least quarterly based on these conditions and record adjustments when necessary.
Inventories

Inventories

 

Inventories, which consist of the Company’s product held for resale, are stated at the lower of cost, determined using the first-in, first-out, or net realizable value. Net realizable value is the estimated selling price, in the ordinary course of business, less estimated costs to complete and dispose of the product.

 

If the Company identifies excess, obsolete or unsalable items, its inventories are written down to their realizable value in the period in which the impairment is first identified. Shipping and handling costs incurred for inventory purchases and product shipments are recorded in cost of sales in the Company’s statements of operations. In the first quarter of 2018 and 2017, the Company recorded a loss of $-0- due to management’s estimate of obsolete inventory. 
Property and Equipment

Property and Equipment

 

Property and equipment are stated at cost. Expenditures for additions are capitalized, repairs and maintenance are expensed as incurred. Depreciation is provided using the straight-line method over the estimated useful lives of the assets, which are as follows: 

 

    March 31, 2018     December 31, 2017  
Machinery and equipment – 7 years   $ 31,801     $ 19,195  
Accumulated depreciation     (9,589 )     (8,603 )
Total property and equipment   $ 22,212     $ 10,592  
Financial Instruments and Fair Value Measurements

Financial Instruments and Fair Value Measurements

 

The fair value of a financial instrument represents the amount at which the instrument could be exchanged in a current transaction between willing parties, other than in a forced sale or liquidation. Fair value estimates are made at a specific point in time, based on relevant market information about the financial instrument. These estimates are subjective in nature and involve uncertainties and matters of judgment, and therefore cannot be determined with precision.

 

Accounting standards define fair value as the price that would be received from selling an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. Accounting standards establish a fair value hierarchy which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value and also establishes the following three levels of inputs that may be used to measure fair value:

 

Level 1 — quoted prices in active markets for identical assets or liabilities

 

Level 2 — Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities

 

Level 3 — Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities

 

The following methods and assumptions were used by the Company in estimating fair value disclosures for financial instruments:

 

● Cash and cash equivalents, restricted cash, operating lease related receivables, and accounts payable: The amounts reported in the accompanying Consolidated Balance Sheets approximate fair value due to their short-term nature

 

● Goodwill, other intangible assets, and long-lived assets held and used: The assets are measured at fair value when there is an indicator of impairment and recorded at fair value only when impairment is recognized or for a business combination. The fair values less costs to sell of long-lived assets or disposal groups held for sale are assessed each reporting period they remain classified as held for sale. Subsequent changes in the held for sale long-lived asset’s or disposal group’s fair value less cost to sell (increase or decrease) are reported as an adjustment to its carrying amount, except that the adjusted carrying amount cannot exceed the carrying amount of the long-lived asset or disposal group at the time it was initially classified as held for sale. [need to add the Level of inputs used]

 
Stock-based compensation

Stock-based compensation

 

The Company recognizes compensation expense for stock-based compensation in accordance with ASC Topic 718. For employee stock-based awards, the fair value of the award is calculated on the date of grant using the Black-Scholes method for stock options and the quoted price of our common stock for common shares; the expense is recognized over the service period for awards expected to vest. For non-employee stock-based awards, the fair value of the award on the date of grant is calculated in the same manner as employee awards. However, the awards are revalued at the end of each reporting period and the pro rata compensation expense is adjusted accordingly until such time the nonemployee award is fully vested, at which time the total compensation recognized to date equals the fair value of the stock-based award as calculated on the measurement date, which is the date at which the award recipient’s performance is complete. The estimation of stock-based awards that will ultimately vest requires judgment, and to the extent actual results or updated estimates differ from original estimates, such amounts are recorded as a cumulative adjustment in the period estimates are revised.
Earnings (Loss) Per Share

Earnings (Loss) Per Share

 

Basic earnings (loss) per share is computed by dividing net income (loss) by the weighted average number of common shares outstanding for the period. Diluted earnings (loss) per share is computed by dividing net income (loss) by the weighted average number of shares outstanding, noted above.
Recent Accounting Pronouncements

Recent Accounting Pronouncements

 

Revenue Recognition

 

As of January 1, 2018, the Company adopted ASU 2014-09 and all subsequent ASUs that modified ASC 606. As part of the implementation process the Company performed an analysis to identify accounting policies that needed to change and additional disclosures that are required. The Company considered factors such as customer contracts with unique revenue recognition considerations, the nature and type of goods and services offered, the degree to which contracts include multiple performance obligations or variable consideration, and the pattern in which revenue is currently recognized, among other things. All of the Company’s revenue streams were evaluated, and similar performance obligations resulted under the new standard. In addition, the Company considered recognition under the new standard and concluded the timing of the Company’s revenue recognition will remain the same. The Company has also evaluated the changes in controls and processes that are necessary to implement the new standard, and no material changes were required.

 

CCI’s revenue predominantly represents consulting services agreements, which included providing services to physicians for billing insurance companies. The amounts reported as revenue are net of amounts remitted.

 

EZ’s revenue from the sale of products are recognized when the sale is consummated and title is transferred. The Company and customer enter into an agreement which outlines the place and date of sale, purchase price, payment terms, and the assignment of rights and warranties from the Company to the customer. Management has identified the promise in the sale contract to be the transfer of ownership of the asset. Management believes the asset holds standalone value to the customer as it is not dependent on any other services for functionality purposes and therefore is distinct within the context of the contract and as described in ASC 606-10. As such, management has identified the transfer of the asset as the performance obligation. The transaction price is set at a fixed dollar amount per fixed quantity (number of assets) and is explicitly stated in each contract. Sales revenue is based on a set price for a set number of assets, which is allocated to the performance obligation discussed above, in its entirety. The Company has determined the date of transfer to the customer to be the date the customer obtains control and title over the asset and the date which revenue is to be recognized and payment is due. As such, there is no impact to the timing and amounts of revenue recognized for equipment sales related to the implementation of ASC 606.

 

Accounting for Leases

 

In February 2016, the FASB issued an accounting standard update that amends the accounting guidance on leases. The intent of this ASU is to increase transparency and comparability among organizations recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements. Lessors will account for leases using an approach that is substantially equivalent to existing U.S. GAAP for sales-type leases, direct financing leases and operating leases. Unlike current guidance, however, a lease with collectability uncertainties may be classified as a sales-type lease. If collectability of lease payments, plus any amount necessary to satisfy a lessee residual value guarantee, is not probable, lease payments received will be recognized as a deposit liability and the underlying assets will not be derecognized until collectability of the remaining amounts becomes probable. The ASU is effective for interim and annual periods beginning after December 15, 2018, with early adoption permitted, and must be adopted using a modified retrospective approach for leases that exist or are entered into after the beginning of the earliest comparative period in the financial statements. The Company plans to adopt this guidance on January 1, 2019, that standard’s effective date, and is currently in the process of determining the impact that the updated accounting guidance will have on the consolidated financial statements and related disclosures. 

 

Classification of Certain Cash Receipts and Cash Payments

 

In August 2016, the FASB issued an accounting standard update that provides guidance on the following eight specific cash flow classification issues: (1) debt prepayment or debt extinguishment costs; (2) settlement of zero-coupon debt instruments or other debt instruments with coupon interest rates that are insignificant in relation to the effective interest rate of the borrowing; (3) contingent consideration payments made after a business combination; (4) proceeds from the settlement of insurance claims; (5) proceeds from the settlement of corporate-owned life insurance policies, including bank-owned life insurance policies; (6) distributions received from equity method investees; (7) beneficial interests in securitization transactions; and (8) separately identifiable cash flows and application of the predominance principle. Current GAAP does not include specific guidance on these eight cash flow classification issues. The amendments of this ASU are effective for reporting periods beginning after December 15, 2017, with early adoption permitted. We will adopt this accounting standard update effective January 1, 2018. The provisions of this update will not have a material impact on our consolidated statements of cash flows. 

 

Tax Cuts and Jobs Act

 

In February 2018, the FASB issued ASU 2018-02, “Income Statement – Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income” to address stakeholder concerns about the guidance in current U.S. GAAP that requires deferred tax liabilities and assets to be adjusted for the effect of a change in tax laws or rates with the effect included in income from continuing operations in the reporting period that includes the enactment date. The amendments in this Update allow a reclassification from accumulated other comprehensive income to retained earnings for stranded tax effects resulting from the Tax Cuts and Jobs Act. The Company is currently evaluating the timing, methods and impact of adopting this new standard on the consolidated financial statements.
XML 26 R17.htm IDEA: XBRL DOCUMENT v3.8.0.1
Summary of Significant Accounting Policies (Tables)
 3 Months Ended
Mar. 31, 2018
Accounting Policies [Abstract]  
Property and Equipment

Depreciation is provided using the straight-line method over the estimated useful lives of the assets, which are as follows: 

 

    March 31, 2018     December 31, 2017  
Machinery and equipment – 7 years   $ 31,801     $ 19,195  
Accumulated depreciation     (9,589 )     (8,603 )
Total property and equipment   $ 22,212     $ 10,592  
XML 27 R18.htm IDEA: XBRL DOCUMENT v3.8.0.1
Acquisition (Tables)
 3 Months Ended
Mar. 31, 2018
Business Combinations [Abstract]  
Consideration of net assets purchased

The following table presents the consideration of net assets purchased:

 

Cash   $ 3,600,000  
1,751,580 shares of common stock issued     175,158  
Note payable     2,500,000  
Imputed interest     (763,558 )
Schedule of allocation of purchase cost

The following table summarizes the fair values assigned to the assets acquired and liabilities assumed.

 

Cash   $ 81,359  
Current assets     759,710  
Other non-current assets     11,167  
Intangible assets     4,313,000  
Goodwill     3,313,226  
Current liabilities     (1,343,880 )
Deferred tax liability     (1,622,982 )
Net assets acquired   $ 5,511,600  
Acquisition, Pro Forma Information
    (Unaudited)
Pro Forma Results
Three months ended March 31,		  
    2017  
       
Revenues   $ 1,232,278  
Income before income taxes   $ 82,224  
         
Basic and fully diluted earnings (loss) per share   $ 0.00  
XML 28 R19.htm IDEA: XBRL DOCUMENT v3.8.0.1
Intangible Assets (Tables)
 3 Months Ended
Mar. 31, 2018
Goodwill and Intangible Assets Disclosure [Abstract]  
Intangible Assets
Amortizing   Estimates   Gross  
Intangible Assets   Useful Life   Carrying Amount  
           
Customer Lists   10 years   $ 2,653,000  
Tradenames   15 years     377,000  
IP Technologies   10 years     819,000  
Non-compete   5 years     464,000  
          4,313,000  
Less: Accumulated Amortization         (232,566 )
             
        $ 4,080,434  
XML 29 R20.htm IDEA: XBRL DOCUMENT v3.8.0.1
Notes payable (Tables)
 3 Months Ended
Mar. 31, 2018
Debt Disclosure [Abstract]  
Schedule of note payable
    March 31,     December 31,  
    2018     2017  
             
Note payable – monthly interest, 12.75% per annum, matures on September 29, 2020   $ 5,000,000     $ 5,000,000  
Less discounts     (411,121 )     (452,233 )
Note payable – monthly interest, 12.75% per annum, matures on September 30, 2022     2,500,000       2,500,000  
Less discounts     (646,157 )     (704,858 )
Subtotal     6,442,722       6,342,909  
Less: current portion, net of discount $399,252     265,196       265,196  
Long- term portion   $ 6,177,526     $ 6,077,713  
Schedule of Principal payments on maturity
Principal payments on the above notes mature as follows:                
Year ending December 31:                
2018   $ 265,196     $ 265,196  
2019     301,057       301,057  
2020     5,341,766       5,341,766  
2021     387,980       387,980  
2022     440,443       440,443  
Thereafter   $ 6,736,442     $ 6,736,442  

 
XML 30 R21.htm IDEA: XBRL DOCUMENT v3.8.0.1
Business Segment Information (Table)
 3 Months Ended
Mar. 31, 2018
Segment Reporting [Abstract]  
Business Segment Information

The following table present selected financial information about the Company’s reportable segments for the three months ended March 31, 2018.

 

For the three months 

ended March 31, 2018 

   Consolidated     Ancillary Program     Prescription Medicine     Corporate  
                         
Revenues   $ 1,924,832     $ 1,444,060     $ 480,772     $ —  
Cost of Revenue     376,096       —       376,096       —  
Long-lived assets     7,415,872       6,395,764       1,020,108       —  
Income (loss) before income tax     188,996       671,897       95,523       (578,424 )
Identifiable assets     4,102,646       3,082,538       1,020,108       —  
Depreciation and amortization     120,179       986       —       119,193  
XML 31 R22.htm IDEA: XBRL DOCUMENT v3.8.0.1
Summary of Significant Accounting Policies (Details) - USD ($)
 3 Months Ended
Mar. 31, 2018
Dec. 31, 2017
Accounting Policies [Abstract]    
Machinery and equipment, estimated useful life 7 years  
Machinery and equipment $ 31,801 $ 19,195
Accumulated depreciation (9,589) (8,603)
Total property and equipment $ 22,212 $ 10,592
XML 32 R23.htm IDEA: XBRL DOCUMENT v3.8.0.1
Summary of Significant Accounting Policies (Details Narrative) - USD ($)
 3 Months Ended
Mar. 31, 2018
Mar. 31, 2017
Accounting Policies [Abstract]    
Obsolete inventory $ 0 $ 0
XML 33 R24.htm IDEA: XBRL DOCUMENT v3.8.0.1
Acquisition (Details) - Common Compounds Inc EzPharmaRx LLC
Sep. 29, 2017
USD ($)
Cash $ 3,600,000
1,751,580 shares of common stock issued 175,158
Note payable 2,500,000
Imputed interest (763,558)
Total Purchase Price $ 5,511,600
XML 34 R25.htm IDEA: XBRL DOCUMENT v3.8.0.1
Acquisition (Details 1) - Common Compounds Inc EzPharmaRx LLC
Sep. 29, 2017
USD ($)
Cash $ 81,359
Current assets 759,710
Other non-current assets 11,167
Intangible assets 4,313,000
Goodwill 5,511,600
Current liabilities (1,343,880)
Deferred tax liability (1,622,982)
Net assets acquired $ 5,511,600
XML 35 R26.htm IDEA: XBRL DOCUMENT v3.8.0.1
Acquisition (Details 2)
 3 Months Ended
Mar. 31, 2017
USD ($)
$ / shares
Business Combinations [Abstract]  
Revenues $ 1,232,278
Income before income taxes $ 82,224
Basic and fully diluted earnings (loss) per share | $ / shares $ 0.00
XML 36 R27.htm IDEA: XBRL DOCUMENT v3.8.0.1
Acquisition (Details Narrative) - USD ($)
 1 Months Ended 12 Months Ended
Sep. 29, 2017
Dec. 31, 2017
Acquisition costs   $ 410,000
Common Compounds Inc EzPharmaRx LLC    
Purchase price $ 6,100,000  
Common stock issued for acquisition 1,751,580  
Cash $ 3,600,000  
Non-interest-bearing note 2,500,000  
Payable $ 500,000  
Interest on non-interest-bearing 12.75%  
Deferred tax liability $ (1,622,982)  
Identifiable intangible assets acquired $ 4,313,000  
Blended tax rate 37.63%  
XML 37 R28.htm IDEA: XBRL DOCUMENT v3.8.0.1
Intangible Assets (Details) - USD ($)
 3 Months Ended
Mar. 31, 2018
Dec. 31, 2017
Intangible Assets, Gross $ 4,313,000  
Less: Accumulated Amortization (232,566)  
Intangible Assets, Net $ 4,080,434 $ 4,196,717
Customer Lists [Member]    
Estimates useful life 10 years  
Intangible Assets, Gross $ 2,653,000  
Trade Names [Member]    
Estimates useful life 15 years  
Intangible Assets, Gross $ 377,000  
IP Technologies [Member]    
Estimates useful life 10 years  
Intangible Assets, Gross $ 819,000  
Noncompete [Member]    
Estimates useful life 5 years  
Intangible Assets, Gross $ 464,000  
XML 38 R29.htm IDEA: XBRL DOCUMENT v3.8.0.1
Intangible Assets (Details Narrative) - USD ($)
 3 Months Ended
Mar. 31, 2018
Mar. 31, 2017
Goodwill and Intangible Assets Disclosure [Abstract]    
Amortization expense related the intangible assets $ 116,283
XML 39 R30.htm IDEA: XBRL DOCUMENT v3.8.0.1
Notes payable (Details) - USD ($)
Mar. 31, 2018
Dec. 31, 2017
Less discounts $ (399,252) $ (399,252)
Subtotal 6,442,722 6,342,909
Less: current portion, net of discount $399,252 265,196 265,196
Long- term portion 6,177,526 6,077,713
Notes Payable One [Member]    
Note payable 5,000,000 5,000,000
Less discounts (411,121) (452,233)
Notes Payable Two [Member]    
Note payable 2,500,000 2,500,000
Less discounts $ (646,157) $ (704,858)
XML 40 R31.htm IDEA: XBRL DOCUMENT v3.8.0.1
Notes payable (Details 1) - USD ($)
Mar. 31, 2018
Dec. 31, 2017
Debt Disclosure [Abstract]    
Year ending December 31 2018 $ 265,196 $ 265,196
Year ending December 31 2019 301,057 301,057
Year ending December 31 2020 5,341,766 5,341,766
Year ending December 31 2021 387,980 387,980
Year ending December 31 2022 440,443 440,443
Thereafter $ 6,736,442 $ 6,736,442
XML 41 R32.htm IDEA: XBRL DOCUMENT v3.8.0.1
Notes payable (Details Narrative) - USD ($)
 1 Months Ended
Sep. 29, 2017
Mar. 31, 2018
Dec. 31, 2017
Common stock issued   22,869,191 22,869,191
Discount   $ 399,252 $ 399,252
Loan costs   $ 6,442,722 $ 6,342,909
Lender      
Financing Cost $ 5,000,000    
Interest rate 12.75%    
Maturity Date Sep. 29, 2020    
Common stock issued 3,584,279    
Price per Share $ 0.10    
Discount $ 493,345    
Loan costs 34,917    
Promissory note 2,500,000    
Common Compounds Inc EzPharmaRx LLC      
Financing Cost $ 2,500,000    
Maturity Date Sep. 30, 2022    
Price per Share $ 2.00    
Annual payment $ 500,000    
Interest imputed rate 12.75%    
Common Compounds Inc EzPharmaRx LLC | Lender      
Common stock issued 3,584,279    
XML 42 R33.htm IDEA: XBRL DOCUMENT v3.8.0.1
Related Party (Details Narrative) - USD ($)
 3 Months Ended 12 Months Ended
Jan. 10, 2018
Mar. 31, 2018
Dec. 31, 2017
Mr. James. Pande [Member] | Secured Promissory [Member]      
Outstanding amount   $ 0 $ 0
Mr. James. Pande [Member] | Secured Promissory [Member] | Minimum [Member]      
Borrowing bear interest rate   2.90%  
Mr. James. Pande [Member] | Secured Promissory [Member] | Maximum [Member]      
Borrowing bear interest rate   7.50%  
Mr. David Hopkins [Member]      
Base Salary $ 175,000 $ 325,000  
Car allowance per month   600  
Unpaid compensation expenses to officers   $ 157,000 182,000
Option granted   525,000  
Option exerciseable price   $ 0.35  
Term   10 years  
Shareholder [Member]      
Related party loan     $ 33,512
XML 43 R34.htm IDEA: XBRL DOCUMENT v3.8.0.1
Stockholders' Equity (Details Narrative) - USD ($)
 1 Months Ended
Sep. 29, 2017
Mar. 31, 2018
Dec. 31, 2017
Common stock, authorized   100,000,000 100,000,000
Common stock, par value (in dollars per share)   $ 0.001 $ 0.001
Stock issued   22,869,191 22,869,191
Preferred stock, authorized   5,000,000 5,000,000
Preferred stock, par value (in dollars per share)   $ 0.001 $ 0.001
Lender      
Stock issued 3,584,279    
Common Compounds Inc EzPharmaRx LLC      
Value of share issued for services $ 5,000,000    
Common Compounds Inc EzPharmaRx LLC | Seller      
Stock issued 1,751,580    
Common Compounds Inc EzPharmaRx LLC | Lender      
Stock issued 3,584,279    
XML 44 R35.htm IDEA: XBRL DOCUMENT v3.8.0.1
2015 Incentive Stock Plan (Details Narrative) - 2015 Stock Option Incentive Plan [Member]
 3 Months Ended
Mar. 31, 2018
$ / shares
shares
Stock issued for option plan 3,000,000
Number of share issued for services 1,266,666
Option exerciseable price | $ / shares $ 0.35
XML 45 R36.htm IDEA: XBRL DOCUMENT v3.8.0.1
Income Taxes (Details Narrative) - USD ($)
 3 Months Ended
Mar. 31, 2018
Dec. 31, 2017
Mar. 31, 2017
Income Tax Disclosure [Abstract]      
Income tax expense $ 51,029 $ 0
Effective tax rates 27.00% 38.50%  
Federal and state net operating loss carryovers $ 566,304    
Operating Loss Carryforwards, Expiration Date Dec. 31, 2031    
Description of utilization of NOLs

Utilization of the NOLs may be subject to limitation under the Internal Revenue Code Section 382 should there be a greater than 50% ownership change as determined under regulations.  

    
Change in tax rate 21.00%    
XML 46 R37.htm IDEA: XBRL DOCUMENT v3.8.0.1
Business Segment Information (Details) - USD ($)
 3 Months Ended
Mar. 31, 2018
Mar. 31, 2017
Revenues $ 1,924,832
Cost of Revenue 376,096
Long-lived assets 7,415,872  
Income (loss) before income tax 188,996 $ (21,119)
Identifiable assets 4,102,646  
Depreciation and amortization 120,179  
Ancillary Program [Member]    
Revenues 1,444,060  
Cost of Revenue  
Long-lived assets 6,395,764  
Income (loss) before income tax 671,897  
Identifiable assets 3,082,538  
Depreciation and amortization 986  
Prescription Medicine [Member]    
Revenues 480,772  
Cost of Revenue 376,096  
Long-lived assets 1,020,108  
Income (loss) before income tax 95,523  
Identifiable assets 1,020,108  
Depreciation and amortization  
Corporate [Member]    
Revenues  
Cost of Revenue  
Long-lived assets  
Income (loss) before income tax (578,424)  
Identifiable assets  
Depreciation and amortization $ 119,193  
XML 47 R38.htm IDEA: XBRL DOCUMENT v3.8.0.1
Business Segment Information (Details Narrative)
 3 Months Ended
Mar. 31, 2018
Number
Segment Reporting [Abstract]  
Number of reportable segment 1
EXCEL 48 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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how.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 50 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 52 FilingSummary.xml IDEA: XBRL DOCUMENT 3.8.0.1 html 44 167 1 false 19 0 false 5 false false R1.htm 00000001 - Document - Document and Entity Information Sheet http://health-right.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) Sheet http://health-right.com/role/CondensedConsolidatedBalanceSheets CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) Statements 2 false false R3.htm 00000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) Sheet http://health-right.com/role/CondensedConsolidatedBalanceSheetsParenthetical CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) Sheet http://health-right.com/role/CondensedConsolidatedStatementsOfOperations CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) Statements 4 false false R5.htm 00000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS(Unaudited) Sheet http://health-right.com/role/CondensedConsolidatedStatementsOfCashFlowsunaudited CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS(Unaudited) Statements 5 false false R6.htm 00000006 - Disclosure - Summary of Significant Accounting Policies Sheet http://health-right.com/role/SummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 6 false false R7.htm 00000007 - Disclosure - Acquisition Sheet http://health-right.com/role/Acquisition Acquisition Notes 7 false false R8.htm 00000008 - Disclosure - Intangible Assets Sheet http://health-right.com/role/IntangibleAssets Intangible Assets Notes 8 false false R9.htm 00000009 - Disclosure - Notes payable Notes http://health-right.com/role/NotesPayable Notes payable Notes 9 false false R10.htm 00000010 - Disclosure - Related Party Sheet http://health-right.com/role/RelatedParty Related Party Notes 10 false false R11.htm 00000011 - Disclosure - Stockholders' Equity Sheet http://health-right.com/role/StockholdersEquity Stockholders' Equity Notes 11 false false R12.htm 00000012 - Disclosure - 2015 Incentive Stock Plan Sheet http://health-right.com/role/IncentiveStockPlan 2015 Incentive Stock Plan Notes 12 false false R13.htm 00000013 - Disclosure - Income Taxes Sheet http://health-right.com/role/IncomeTaxes Income Taxes Notes 13 false false R14.htm 00000014 - Disclosure - Business Segment Information Sheet http://health-right.com/role/BusinessSegmentInformation Business Segment Information Notes 14 false false R15.htm 00000015 - Disclosure - Subsequent events Sheet http://health-right.com/role/SubsequentEvents Subsequent events Notes 15 false false R16.htm 00000016 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://health-right.com/role/SummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://health-right.com/role/SummaryOfSignificantAccountingPolicies 16 false false R17.htm 00000017 - Disclosure - Summary of Significant Accounting Policies (Tables) Sheet http://health-right.com/role/SummaryOfSignificantAccountingPoliciesTables Summary of Significant Accounting Policies (Tables) Tables http://health-right.com/role/SummaryOfSignificantAccountingPolicies 17 false false R18.htm 00000018 - Disclosure - Acquisition (Tables) Sheet http://health-right.com/role/AcquisitionTables Acquisition (Tables) Tables http://health-right.com/role/Acquisition 18 false false R19.htm 00000019 - Disclosure - Intangible Assets (Tables) Sheet http://health-right.com/role/IntangibleAssetsTables Intangible Assets (Tables) Tables http://health-right.com/role/IntangibleAssets 19 false false R20.htm 00000020 - Disclosure - Notes payable (Tables) Notes http://health-right.com/role/NotesPayableTables Notes payable (Tables) Tables http://health-right.com/role/NotesPayable 20 false false R21.htm 00000021 - Disclosure - Business Segment Information (Table) Sheet http://health-right.com/role/BusinessSegmentInformationTable Business Segment Information (Table) Tables http://health-right.com/role/BusinessSegmentInformation 21 false false R22.htm 00000022 - Disclosure - Summary of Significant Accounting Policies (Details) Sheet http://health-right.com/role/SummaryOfSignificantAccountingPoliciesDetails Summary of Significant Accounting Policies (Details) Details http://health-right.com/role/SummaryOfSignificantAccountingPoliciesTables 22 false false R23.htm 00000023 - Disclosure - Summary of Significant Accounting Policies (Details Narrative) Sheet http://health-right.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative Summary of Significant Accounting Policies (Details Narrative) Details http://health-right.com/role/SummaryOfSignificantAccountingPoliciesTables 23 false false R24.htm 00000024 - Disclosure - Acquisition (Details) Sheet http://health-right.com/role/AcquisitionDetails Acquisition (Details) Details http://health-right.com/role/AcquisitionTables 24 false false R25.htm 00000025 - Disclosure - Acquisition (Details 1) Sheet http://health-right.com/role/AcquisitionDetails1 Acquisition (Details 1) Details http://health-right.com/role/AcquisitionTables 25 false false R26.htm 00000026 - Disclosure - Acquisition (Details 2) Sheet http://health-right.com/role/AcquisitionDetails2 Acquisition (Details 2) Details http://health-right.com/role/AcquisitionTables 26 false false R27.htm 00000027 - Disclosure - Acquisition (Details Narrative) Sheet http://health-right.com/role/AcquisitionDetailsNarrative Acquisition (Details Narrative) Details http://health-right.com/role/AcquisitionTables 27 false false R28.htm 00000028 - Disclosure - Intangible Assets (Details) Sheet http://health-right.com/role/IntangibleAssetsDetails Intangible Assets (Details) Details http://health-right.com/role/IntangibleAssetsTables 28 false false R29.htm 00000029 - Disclosure - Intangible Assets (Details Narrative) Sheet http://health-right.com/role/IntangibleAssetsDetailsNarrative Intangible Assets (Details Narrative) Details http://health-right.com/role/IntangibleAssetsTables 29 false false R30.htm 00000030 - Disclosure - Notes payable (Details) Notes http://health-right.com/role/NotesPayableDetails Notes payable (Details) Details http://health-right.com/role/NotesPayableTables 30 false false R31.htm 00000031 - Disclosure - Notes payable (Details 1) Notes http://health-right.com/role/NotesPayableDetails1 Notes payable (Details 1) Details http://health-right.com/role/NotesPayableTables 31 false false R32.htm 00000032 - Disclosure - Notes payable (Details Narrative) Notes http://health-right.com/role/NotesPayableDetailsNarrative Notes payable (Details Narrative) Details http://health-right.com/role/NotesPayableTables 32 false false R33.htm 00000033 - Disclosure - Related Party (Details Narrative) Sheet http://health-right.com/role/RelatedPartyDetailsNarrative Related Party (Details Narrative) Details http://health-right.com/role/RelatedParty 33 false false R34.htm 00000034 - Disclosure - Stockholders' Equity (Details Narrative) Sheet http://health-right.com/role/StockholdersEquityDetailsNarrative Stockholders' Equity (Details Narrative) Details http://health-right.com/role/StockholdersEquity 34 false false R35.htm 00000035 - Disclosure - 2015 Incentive Stock Plan (Details Narrative) Sheet http://health-right.com/role/IncentiveStockPlanDetailsNarrative 2015 Incentive Stock Plan (Details Narrative) Details http://health-right.com/role/IncentiveStockPlan 35 false false R36.htm 00000036 - Disclosure - Income Taxes (Details Narrative) Sheet http://health-right.com/role/IncomeTaxesDetailsNarrative Income Taxes (Details Narrative) Details http://health-right.com/role/IncomeTaxes 36 false false R37.htm 00000037 - Disclosure - Business Segment Information (Details) Sheet http://health-right.com/role/BusinessSegmentInformationDetails Business Segment Information (Details) Details http://health-right.com/role/BusinessSegmentInformationTable 37 false false R38.htm 00000038 - Disclosure - Business Segment Information (Details Narrative) Sheet http://health-right.com/role/BusinessSegmentInformationDetailsNarrative Business Segment Information (Details Narrative) Details http://health-right.com/role/BusinessSegmentInformationTable 38 false false All Reports Book All Reports cik0001537663-20180331.xml cik0001537663-20180331.xsd cik0001537663-20180331_cal.xml cik0001537663-20180331_def.xml cik0001537663-20180331_lab.xml cik0001537663-20180331_pre.xml http://fasb.org/us-gaap/2018-01-31 http://fasb.org/srt/2018-01-31 http://xbrl.sec.gov/dei/2018-01-31 true true ZIP 54 0001615774-18-003642-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001615774-18-003642-xbrl.zip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